Pharmacology Biochemistry & Behavior, Vol. 16. Copyright © 1982 by Ankho International Inc. Printed in the U.S.A.

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 16 1982

SUBJECT INDEX

Abrin, 185
  DNA synthesis
  human peripheral lymphocytes
  protein synthesis
  virus transformed lymphocytes
Abstinence syndrome, 725
  continuous infusion
  dependence liability
  narcotics
  opiates
Abuse potential, 851
  d,l-glaucine·1.5 phosphate
  rhesus monkeys
  self-administration
Acetylcholine, 533
  catalepsy
  dopamine
  neuroleptics
  postnatal development
Acquisition, 943
  avoidance
  extinction
  intertrial response
  shuttlebox
  TRH
$ACTH_{4-10}$, 387
  [D-Phe^7]$ACTH_{4-10}$, potency and duration
  active avoidance
  ORG 2766, potency and duration
  passive avoidance
[D-Phe^7]$ACTH_{4-10}$, potency and duration, 387
  $ACTH_{4-10}$
  active avoidance
  ORG 2766, potency and duration
  passive avoidance
Active avoidance
  $ACTH_{4-10}$, 387
  [D-Phe^7]$ACTH_{4-10}$, potency and duration, 387
  anxiety, 467
  anxiolytics, 467
  barbital, 467
  barbiturates, 467
  brain drug levels, 467
  central monoamines, 881
  p-chloroamphetamine, 881
  drug administration, chronic, 467
  ORG 2766, potency and duration, 387
  passive avoidance, 387
  righting reflex, 467
  serotonin release, 881
  tolerance, 467
Activity, 411
  cold water swims
  drug interaction
  neuroleptics
  opiate analgesia
  pain
Acute drug pretreatment, 847
  chronic drug pretreatment
  drug interaction
  ethanol
  phencyclidine
Acute venous catheterization, 521
  blood sample collection
  integrated plasma sampling
  primates
Adrenal medulla, 719
  catecholamines
  ethanol
  physical dependence
  withdrawal syndrome
Adrenalectomy, 403
  analgesia
  dexamethasone
  pain
  stress
β-Adrenoceptor antagonists, 741
  dopamine
  hyponeophagia
  5-MeODMT
  neophobia
  serotonin
Afterdischarge threshold
  amygdala, 1009
  cocaine, 855
  kindling, 1009
  kindling, olfactory bulb, 855
  phencyclidine, 1009
  seizures, 1009
Age differences, 217
  amphetamine
  avoidance
  catecholamines
  maturation
  motor activity
Aggression
  androgens, 41
  ataxia, 63
  catecholamines, 359
  cocaine, 359
  dopaminergic system, 547
  footshock, 63
  hallucinogens, 63
  hypothalamus, 41
  isolation-induced, 359
  lesions, 6-OHDA, 547
  locomotor activity, 569
  mesocorticolimbic system, 547
  methadone, 569
  muricide, 547

social behavior, 569
ventral mesenceaphlic tegmental area (nucleus A10), 547
Aggressive behavior
brain monoamines, 73
dietary tyrosine, 73
fusaric acid, 73
GABA, 57
inbred mouse strains, 57
isolation, 57
mice, 73
motor activity, 73
Albinism, 815
pentobarbital
response duration
sex differences
Alcohol
amine-aldehyde condensation product, 827
calcium-sodium ratio, 321
dopamine, 321
drinking, 707, 827
drug interaction, 707
ethanol, 321
hypothermia, 321
Maudsley rats, 707
morphine, 707
naloxone, 827
norepinephrine, 321
opiate receptors, 827
poikilothermia, 321
salsolinol, 827
selective breeding, 707
serotonin (5-HT), 321
strain differences, 707
temperature set-point, 321
tetrahydropapaveroline, 827
thermoregulation, 321
Alcohol dependence, 253
conditioned taste aversion
stress
withdrawal
Alcohol-opiate commonalities, 35
ethanol sensitivity
morphine withdrawal
opiate dependence
Alcohol preference
dopamine, 145
drinking, 501
ethanol concentration and distribution, 125
ethanol sensitivity, 125
free-choice alcohol consumption, 501
5-hydroxyindoleacetic acid, 145
norepinephrine, 145
physical dependence, 501
regional brain monoamines, 145
selective breeding, 125, 501
serotonin, 145
withdrawal, 501
Aldosterone, 697
angiotensin II
food deprivation
hypovolemia
plasma osmolality
sodium retention
Alpha adrenergic antagonists, 731
alpha-2 receptors
autonomic responses
extrapyramidal effects
motor responses
reserpine rigidity
Alpha-2 receptors, 731
alpha adrenergic antagonists
autonomic responses
extrapyramidal effects
motor responses
reserpine rigidity
Ambient temperature, 903
blood glucose levels
body temperature
ethanol
hypothermia
tolerance
Amine-aldehyde condensation product, 827
alcohol
drinking
naloxone
opiate receptors
salsolinol
tetrahydropapaveroline
Amine-aldehyde metabolites, 995
drug interaction
ethanol self-selection
macaque monkey, female
route of delivery
tetrahydropapaveroline, ICV infusion
Amnesia, 463
anisomycin
memory retrieval
passive avoidance
vasopressin
Amphetamine
age differences, 217
animal models, hyperactivity, 1
anorexia, 303
apomorphine, 875
avoidance, 217
brain weight, 631
caloric intake, 303
carbohydrate, 303
castration, 565
catecholamines, 217
cocaine, 631
dietary self-selection, 303
dopaminergic supersensitivity, 1
dorsal tegmentum, 433
eating, 303
estrogen, 875
fat, 303
fenfluramine, 303
hyperactivity, haloperidol-induced, 1
lead acetate, 631
lithium, 1
maturation, 217
methylphenidate, 1
motor activity, 217
mouse genotype, 631
naloxone, 433
neonatal rats, 1
ovariectomy, 565
prefrontal cortex, 433
progesterone, 875
protein, 303
reward, 433
seizures, 631
self-stimulation, 433
sex differences, 565
sexual behavior, female rat, 875
stereotyped behavior, 565, 875
d-Amphetamine, 791
bupropion
pipradrol
self-stimulation
Amygdala, 1009
afterdischarge thresholds
kindling
phencyclidine
seizures
Analgesia
adrenalectomy, 403
antiganglioside serum, 611
capsaicin, 241

choleragenoid, 611
dexamethasone, 403
diazepam, 1005
drug interaction, 1005
GM1 ganglioside, 611
meperidine, 1005
morphine, 869
morphine receptors, 611
neonatal treatment, 241
nociceptive stimuli, 241, 869
normeperidine, 1005
opiates, 81
pain, 403
proconvulsive effects, 1005
self-stimulation, 81
startle reflex, 869
stress, 403
Androgen receptor, 837
5α-androstane-3β,17β-diol
estrogen receptors
hypothalamic cytosol
lordosis
mounting behavior
ovariectomy
sexual behavior, female rat
Androgens, 41
aggression
hypothalamus
5α-Androstane-3β,17β-diol, 837
androgen receptors
estrogen receptors
hypothalamic cytosol
lordosis
mounting behavior
ovariectomy
sexual behavior, female rat
Anesthetics, local, 491
drug discrimination
reinforcement
self-administration
species differences
Angiotensin II
aldosterone, 697
drinking, 87
food deprivation, 697
hyperosmolarity, 87
hypovolemia, 87, 697
naloxone, 87
opioids, 87
plasma osmolality, 697
sodium retention, 697
Animal models, hyperactivity, 1
amphetamine
dopaminergic supersensitivity
hyperactivity, haloperidol-induced
lithium
methylphenidate
neonatal rats
Anisomycin, 463
amnesia
memory retrieval
passive avoidance
vasopressin
Anorexia, 303
amphetamine
caloric intake
carbohydrate
dietary self-selection
eating
fat
fenfluramine
protein
Antiapomorphine effect, 311
chronic administration
circadian rhythm
haloperidol
Anticholinergic drugs, 919
memory, spatial
memory, working
scopolamine
Anticonvulsants
convulsions, drug-induced, 177
convulsions, electroshock-induced, 177
electrocortical afterdischarges, 177
fixed-ratio schedule, 843
5-OH-5-ethyl-5-phenyl-butiramide, 177
phenytoin, 843
pigeons, 843
tolerance, 843
Antidepressants
anxiolytics, 449, 965
appetite, 965
buprion, 973
chronic stress, 965
defecation, 969
depressants, 449
depression, 449
depression, animal model, 965, 969, 973
electroconvulsive shock, 449
hedonic deficit, 965
imipramine, 965, 969
iprindole, 973
learned helplessness, 449
mianserine, 973
neuroleptics, 449
open field, 969
plasma corticosterone, 973
stimulants, 449
stress, 969, 973
Antiganglioside serum, 611
analgesia
choleragenoid
GM1 ganglioside
morphine receptors
Antihistamines, 979
anxiolytics
benzodiazepine
corticosterone
defecation
depression, animal model
haloperidol
neuroleptics
open field
oxazepam
tripelennamine
Antileptazol, 529
anxiolytics
benzodiazepine receptors
camazepam
clobazam
diazepam binding
oxazepam
temazepam
Antinociception, 47
dopamine
norepinephrine
serotonin
stress
tail-flick
Anxiety
active avoidance, 467
anxiolytics, 467
barbital, 467
barbiturates, 467
brain drug levels, 467
chlordiazepoxide, 689
conditioned emotional response, 329
convulsant benzodiazepine, 689
drug administration, chronic, 467
GABA, 329, 689

neurotransmitter metabolism, 329
righting reflex, 467
Ro 5-3663, 689
shock history, 329
stress, 329
tolerance, 467
Anxiolytics
active avoidance, 467
antidepressants, 449, 965
antihistamines, 979
antileptazol, 529
anxiety, 467
appetite, 965
barbital, 467
barbiturates, 467
benzodiazepine, 979
benzodiazepine receptors, 529
brain drug levels, 467
camazepam, 529
chronic stress, 965
clobazam, 529
corticosterone, 979
defecation, 979
depressants, 449
depression, 449
depression, animal model, 965, 979
diazepam binding, 529
drug administration, chronic, 467
electroconvulsive shock, 449
haloperidol, 979
hedonic deficit, 965
imipramine, 965
learned helplessness, 449
neuroleptics, 449, 979
open field, 979
oxazepam, 529, 979
righting reflex, 467
stimulants, 449
temazepam, 529
tolerance, 467
tripelennamine, 979
Apomorphine
amphetamine, 875
dopamine, 859
dopaminergic agonists, 235
estrogen, 875
extinction, 859
progesterone, 875
self-stimulation, 859
sexual behavior, female rat, 875
stereotypy, 235, 859, 875
striatal dopamine receptors, 235
Apparatus
breath ethanol analyzer, 693
one compartment electrochemical detector cell, 641
primate equilibrium platform, 605
rotometer, 353
Appetite
antidepressants, 965
anxiolytics, 965
bicuculline, 225
bombesin, 225, 701
bromergocryptine, 701
calcitonin, 225
cholecystokinin octapeptide, 225, 701
chronic stress, 965
depression, animal model, 965
dopaminergic system, 701
drinking, 909
dynorphin, 701
eating, 225, 701, 909
hedonic deficit, 965
histidyl-proline diketopiperazine, 225
imipramine, 965
naloxone, 225
naltrexone, 909
norepinephrine-induced feeding, 225
opiates, 701
renal electrolyte excretion, 909
renal water excretion, 909
satiety, 701
thyrotropin-releasing hormone, 225, 701
water exchange, 909
Arecoline, 677
central cholinergic mechanisms
ferret
nicotine
oxotremorine
predatory behavior
scopolamine
Arousal, 929
grooming
homeostasis
morphine withdrawal syndrome
RX 336-M
wet-dog shakes
Aspartate, 509
dopamine
GABA
glutamate
morphine self-administration
neurotransmitter turnover rates
norepinephrine
opiate reinforcement systems
serotonin
Asymmetry, 455
catecholamines
lesions, electrolytic
lesions, nigrostriatal
lesions, 6-OHDA
lesions, substantia nigra
sensorimotor dysfunction
sensory extinction
Ataxia
aggression, 63
behavioral toxicology, 801
footshock, 63
hallucinogens, 63
hypoactivity, 801
lethality, 801
lithium isotopes, 801
Atropine methylnitrate, 423
atropine sulfate
lever pressing
motor control
rhesus monkey
Atropine sulfate, 423
atropine methylnitrate
lever pressing
motor control
rhesus monkey
Attention, 377
catecholamine interactions
dopamine
gerbils
habituation
locomotor activity
norepinephrine
sex differences
Automatic recording, 353
circling behavior
rotometer
Autonomic responses, 731
alpha adrenergic antagonists
alpha-2 receptors
extrapyramidal effects
motor responses
reserpine rigidity
Autoshaped behavior
exploratory behavior, 937

morphine-induced behavior suppression, 621
opiate receptor alkylators, 621
phencyclidine, 937
Avoidance
acquisition, 943
age differences, 217
amphetamine, 217
catecholamines, 217
extinction, 943
intertrial response, 943
maturation, 217
motor activity, 217
neuroleptics, 541
reversal learning, 541
shuttlebox, 943
spatial preference, 541
striatectomy, 541
TRH, 943
Y-maze performance, 541
Avoidance training, 805
cholinergic system
developmental psychopharmacology
response latency
scopolamine

Barbital, 467
active avoidance
anxiety
anxiolytics
barbiturates
brain drug levels
drug administration, chronic
righting reflex
tolerance
Barbiturates
active avoidance, 467
anxiety, 467
anxiolytics, 467
barbital, 467
brain drug levels, 467
drug administration, chronic, 467
GABA, 737
phenobarbital, 737
righting reflex, 467
rotation, 737
substantia nigra, 737
tolerance, 467
Behavior disruption, 811
kinetic isotope effect
proteo-N,N-dimethyltryptamine
tetradeutero-N,N-dimethyltryptamine
Behavioral arousal, 667
dopamine
extinction
multiple schedule
operant responding
pimozide
reinforcement
successive discrimination
Behavioral effects, 819
neurohypophyseal hormone analogs
oxytocin
structure-activity
vasopressin
Behavioral efficacy, 841
isolation rearing
opiates
receptor binding
Behavioral tolerance, 647
cerebral cortex
fixed-ratio responding
neurotransmitter receptor binding
phencyclidine

Behavioral toxicology, 801
ataxia
hypoactivity
lethality
lithium isotypes
Benactyzine, 605
operant behavior
primate equilibrium platform
rhesus monkey
Benzodiazepine
antihistamines, 979
anxiolytics, 979
benzodiazepine receptors, 29
corticosterone, 979
cyclic GMP, 29
defecation, 979
depression, animal model, 979
diazepam, 29
GABA, 29
haloperidol, 979
neuroleptics, 979
open field, 979
ouabain, 29
oxazepam, 979
tripelennamine, 979
Benzodiazepine receptors
antileptazol, 529
anxiolytics, 529
benzodiazepines, 29
brain, ovine, 373
camazepam, 529
clobazam, 529
cyclic GMP, 29
diazepam, 29, 245
diazepam binding, 529
^{3}H-diazepam binding, 373
GABA, 29
ligand binding, 245
multicomponent receptor, 245
ouabain, 29
oxazepam, 529
photoaffinity labeling, 245
propyl-β-carboline-3-carboxylate, 245
sparing from inactivation, 245
temazepam, 529
triazolopyridazine CL218,872, 373
Bicuculline
appetite, 225
bombesin, 225
calcitonin, 225
cholecystokinin octapeptide, 225
dorsal periaqueductal gray, 397
eating, 225
electrical stimulation, 397
flight behavior, 397
GABA mediation, 397
histidyl-proline diketopiperazine, 225
naloxone, 225
norepinephrine-induced feeding, 225
picrotoxin, 397
thyrotropin releasing hormone, 225
tranquilizers, 297
Biogenic amine metabolites, 641
biogenic monoamine turnover
dopamine
HPLC
norepinephrine
one compartment electrochemical detector cell
serotonin
Biogenic monoamine turnover, 641
biogenic amine metabolites
dopamine
HPLC
norepinephrine
one compartment electrochemical detector cell

serotonin
Blood ethanol, 693
breath ethanol analyzer
repeated sampling
Blood glucose levels, 903
ambient temperature
body temperature
ethanol
hypothermia
tolerance
Blood sample collection, 521
acute venous catheterization
integrated plasma sampling
primates
Body temperature
ambient temperature, 903
blood glucose levels, 903
brain-blood ethanol, 341
capsaicin, 23
ethanol, 903
ethanol antagonists, 341
ethanol metabolism, 341
ethanol narcosis, 341
hyperbaric pressure, 341
hypothalamic temperature, 23
hypothermia, 903
thermoregulation, 23
tolerance, 903
Body weight, 933
eating
prepubertal male rat
testosterone
Bombesin
appetite, 225, 701
bicuculline, 225
bromergocryptine, 701
calcitonin, 225
cholecystokinin octapeptide, 225, 701
dopaminergic system, 701
dynorphin, 701
eating, 225, 701
histidyl-proline diketopiperazine, 225
naloxone, 225
norepinephrine-induced feeding, 225
opiates, 701
satiety, 701
thyrotropin-releasing hormone, 225, 701
Brain
adrenal cortex, 403
adrenal medulla, 719
amygdala, 57, 315, 637, 751, 1009
capsaicin, 23
caudate nucleus, 509
central periaqueductal gray, 433
cerebellum, 29, 245, 373, 529
cerebral cortex, 145, 229, 315, 637, 647, 881
cerebral ventricle, 131
corpus striatum, 145, 915
cortex, 591, 915
dorsal periaqueductal gray, 397
dorsal raphe, 7
dorsal tegmentum, 433
frontal cortex, 139, 373
globus pallidus, 509
hippocampus, 17, 145, 139, 245, 315, 373, 881, 915
hypothalamus, 17, 23, 41, 145, 229, 315, 585, 591, 637, 837, 881
lateral cerebral ventricle, 995
lateral hypothalamus, 433
locus coeruleus, 615
medial forebrain bundle, 7
medulla oblongata, 315
medulla-pons, 139
mesolimbic area, 119
midbrain, 591, 881
neostriatum, 151
nigrostriatum, 455
nucleus accumbens septi, 211
occipital cortex, 139
olfactory bulb, 57, 139, 855
olfactory tubercles, 229
paraventricular hypothalamic nucleus, 101
parietal cortex, 139, 373
pars reticulata, 737
periacqueductal gray, 611
pituitary, 585
pons, 315
pons-medulla, 145, 229, 637
posterior colliculus, 57
prefrontal cortex, 433
putamen, 509
raphe nucleus, 51
septum, 57, 139, 211, 769
spinal cord, 881
striatum, 57, 119, 139, 229, 235, 245, 285, 373, 541, 881
substantia nigra, 455, 737
temporal cortex, 373
thalamus, 139, 145, 315
ventral mesencephalic tegmental area (nucleus A10), 547
ventromedial hypothalamus, 93, 293
Brain-blood ethanol, 341
body temperature
ethanol antagonists
ethanol metabolism
ethanol narcosis
hyperbaric pressure
Brain drug levels, 467
active avoidance
anxiety
anxiolytics
barbital
barbiturates
drug administration, chronic
righting reflex
tolerance
Brain monoamines, 73
aggressive behavior
dietary tyrosine
fusaric acid
mice
motor activity
Brain, mouse, 139
cyclic AMP
vasopressin
Brain, ovine, 373
benzodiazepine receptors
^{3}H-diazepam binding
triazolopyridazine CL218,872
Brain perfusion, 131
dihydroxyphenylacetic acid
endogenous dopamine metabolites
homovanillic acid
HPLC
5-hydroxyindoleacetic acid
Brain region differences
footshock, 637
MHPG-SO_4, 315, 637
noradrenaline turnover, 315, 637
plasma corticosterone, 315
stress, 637
stress, immobilization, 315
time-related differences
Brain weight, 631
amphetamine
cocaine
lead acetate
mouse genotype
seizures
Breath ethanol analyzer, 693
blood ethanol
repeated sampling

Bromergocryptine, 701
appetite
bombesin
cholecystokinin octapeptide
dopaminergic system
dynorphin
eating
opiates
satiety
thyrotropin-releasing hormone
Brown adipose tissue, 627
isoproterenol
obesity
thermogenesis
Zucker rats
Buprion, 973
antidepressants
depression, animal model
iprindole
mianserine
plasma corticosterone
stress
Bupropion, 791
d-amphetamine
pipradrol
self-stimulation
Butorphanol, 167
drug self-administration
morphine-dependent rats
nalbuphine
pentazocine
physical dependence

Caffeine, 745
rate-dependency
schedule-controlled responding
time course
Calcitonin, 225
appetite
bicuculline
bombesin
cholecystokinin octapeptide
eating
histidyl-proline diketopiperazine
naloxone
norepinephrine-induced feeding
thyrotropin releasing hormone
Calcium-sodium ratio, 321
alcohol
dopamine
ethanol
hypothermia
norepinephrine
poikilothermia
serotonin (5-HT)
temperature set-point
thermoregulation
Caloric intake, 303
amphetamine
anorexia
carbohydrate
dietary self-selection
eating
fat
fenfluramine
protein
Caloric intake patterns, 949
carbohydrate
dietary self-selection
eating
β-endorphin
fat
morphine
protein
Camazepam, 529
antileptazol
anxiolytics
benzodiazepine receptors
clobazam
diazepam binding
oxazepam
temazepam
Capsaicin
analgesia, 241
body temperature, 23
hypothalamic temperature, 23
neonatal treatment, 241
nociceptive stimuli, 241
thermoregulation, 23
Carbohydrate
amphetamine, 303
anorexia, 303
caloric intake, 303
caloric intake patterns, 949
dietary self-selection, 303, 949
eating, 303, 949
β-endorphin, 949
fat, 303, 949
fenfluramine, 303
morphine, 949
protein, 303, 949
Cardiac mass, 207
ethanol
mitochondrial function
swimming
Castration, 565
amphetamine
ovariectomy
sex differences
stereotyped behavior
Catalepsy, 533
acetylcholine
dopamine
neuroleptics
postnatal development
Catecholamine interactions, 377
attention
dopamine
gerbils
habituation
locomotor activity
norepinephrine
sex differences
Catecholamines
adrenal medulla, 719
age differences, 217
aggression, isolation-induced, 359
amphetamine, 217
asymmetry, 455
avoidance, 217
cocaine, 359
convulsions, tonic, 441
devleopment, 441
electroshock, 441
ethanol, 719
isolation, 417
lesions, electrolytic, 455
lesions, nigrostriatal, 455
lesions, 6-OHDA, 455
lesions, substantia nigra, 455
maturation, 217
monoamines, 441
motor activity, 217
physical dependence, 719
play, 417
psychomotor stimulants, 417
sensorimotor dysfunction, 455
sensory extinction, 455

serotonin, 441
social behavior, 417
withdrawal syndrome, 719
Cats, 51
hallucinogens
LSD
serotonin (5-HT)
l-tryptophan
visual evoked responses
Central cholinergic mechanisms, 677
arecoline
ferret
nicotine
oxotremorine
predatory behavior
scopolamine
Central monoamines, 881
active avoidance
p-chloroamphetamine
serotonin release
Central reward mechanisms, 1013
drinking
eating
naloxone
naltrexone
operant behavior
opiate antagonists
Cerebral asymmetry, 915
copper
hippocampus
lateralization
spatial behavior
zinc
Cerebral cortex, 647
behavioral tolerance
fixed-ratio responding
neurotransmitter receptor binding
phencyclidine
Chained schedule, 271
drug interactions
fixed interval
methadone
pentobarbital
pigeons
Chlordiazepoxide
anxiety, 689
CL218,872, 795
conflict, 795
convulsant benzodiazepine, 689
diazepam, 795
extinction, 279
GABA, 689
6-hydroxydopamine, neonatal, 279
norepinephrine depletion, 279
pentobarbital, 795
punishment-conflict, 279
Ro 5-3663, 689
self-stimulation, 795
shuttlebox, 795
p-Chloroamphetamine
active avoidance, 881
central monoamines, 881
p-chlorophenylalanine, 957
diazepam, 957
dopaminergic mechanisms, 957
haloperidol, 957
pemoline, 957
pimozide, 957
self-injury, 957
serotonin release, 881
p-Chlorophenylalanine
p-chloroamphetamine, 957
diazepam, 957
dopaminergic mechanisms, 957
haloperidol, 957
5-hydroxytryptophan, 777
lordosis, 777
noradrenaline, 777
pemoline, 957
pimozide, 957
self-injury, 957
serotonin, 777
sexual behavior, female rat, 777
Cholecystokinin octapeptide (CCK-8)
appetite, 225, 701
bicuculline, 225
bombesin, 225, 701
bromergocryptine, 701
calcitonin, 225
dopaminergic system, 701
dynorphin, 701
eating, 225, 701
histidyl-proline diketopiperazine, 225
naloxone, 225
norepinephrine-induced feeding, 225
opiates, 701
satiety, 701
thyrotropin releasing hormone, 225, 701
Choleragenoid, 611
analgesia
antiganglioside serum
GM1 ganglioside
morphine receptors
Cholinergic system, 805
avoidance training
developmental psychopharmacology
response latency
scopolamine
Chronic administration, 311
antiapomorphine effect
circadian rhythm
haloperidol
Chronic drug pretreatment, 847
acute drug pretreatment
drug interaction
ethanol
phencyclidine
Chronic ethanol intake, 155
drinking
overdrinking
schedule-induced polydipsia
Chronic opiate administration, 263
hyperactivity
hypoactivity
in utero studies, rats
morphine tolerance
spontaneous activity, fetal rat
withdrawal
Chronic stress, 965
antidepressants
anxiolytics
appetite
depression, animal model
hedonic deficit
imipramine
Chronic treatment, 757
ethanol dependence
ethanol elimination rates
gender differences
Circadian rhythm, 311
antiapomorphine effect
chronic administration
haloperidol
Circling behavior, 353
automatic recording
rotometer
CL218,872, 795
chlordiazepoxide
conflict
diazepam

pentobarbital
self-stimulation
shuttlebox
Clobazam, 529
antileptazol
anxiolytics
benzodiazepine receptors
camazepam
diazepam binding
oxazepam
temazepam
Clonidine, 785
clozapine
haloperidol
methocarbamol
metoclopramide
prazosin
self-stimulation
shuttlebox
Clorgyline, 429
drug administration, "lifetime"
drug administration, subacute
monoamine oxidase
REM sleep
sleep stages
Clozapine, 785
clonidine
haloperidol
methocarbamol
metoclopramide
prazosin
self-stimulation
shuttlebox
Cobalt epilepsy, 573
marijuana cannabinoids
REM sleep
seizures, epileptic
tetrahydrocannabinols
Cocaine
afterdischarge threshold, 855
aggression, isolation-induced, 359
amphetamine, 631
brain weight, 631
catecholamines, 359
conditional discrimination, 713
conditional drug states, 661
conditioned taste aversion, 347
cross-potentiation, 661
kindling, olfactory bulb, 855
lead acetate, 631
matching-to-sample, 713
memory, 713
mouse genotype, 631
Pavlovian conditioning, 661
pentobarbital, 661
pigeons, 713
seizures, 631
tolerance, 661, 713
Cold water swims, 411
activity
drug interaction
neuroleptics
opiate analgesia
pain
Concurrent schedules
drinking, 113, 393
drug concentration, 113
drug self-administration, oral, 113
ethanol, 393
fixed ratio schedules, 113
pentobarbital reinforcement, 113
reinforcement, 393
relative responding, 393
rhesus monkeys, 113
water intake, 113
Conditional discrimination, 713
cocaine
matching-to-sample
memory
pigeons
tolerance
Conditional drug states, 661
cocaine
cross-potentiation
Pavlovian conditioning
pentobarbital
tolerance
Conditioned emotional response, 329
anxiety
GABA
neurotransmitter metabolism
shock history
stress
Conditioned taste aversion
alcohol dependence, 253
cocaine, 253, 347
stress, 253
withdrawal, 253
Conflict, 795
chlordiazepoxide
CL218,872
diazepam
pentobarbital
self-stimulation
shuttlebox
Continuous infusion, 725
abstinence syndrome
dependence liability
narcotics
opiates
Contralateral turning behavior, 7
dopaminergic system
dorsal raphe lesion
5-HT receptor
5-methoxy-N,N-dimethyltryptamine
Convulsant benzodiazepine, 689
anxiety
chlordiazepoxide
GABA
Ro 5-3663
Convulsions, drug-induced, 177
anticonvulsants
electrocortical afterdischarges
electroshock-induced
5-OH-5-ethyl-5-phenyl-butiramide
Convulsions, electroshock-induced, 177
anticonvulsants
drug-induced
electrocortical afterdischarges
5-OH-5-ethyl-5-phenyl-butiramide
Convulsions, tonic, 441
catecholamines
development
electroshock
monoamines
serotonin
Copper, 915
cerebral asymmetry
hippocampus
lateralization
spatial behavior
zinc
Corticosterone
antihistamines, 979
anxiolytics, 979
benzodiazepine, 979
defecation, 979
depression, animal model, 979
fetal ethanol, 585
haloperidol, 979

hypothalamic-pituitary-adrenal system, 585
neuroleptics, 979
open field, 979
oxazepam, 979
prenatal ethanol, 585
stress, 585
tripelennamine, 979
Cross-potentiation, 661
cocaine
conditional drug states
Pavlovian conditioning
pentobarbital
tolerance
Cyclic AMP, 139
brain, mouse
vasopressin
Cyclic GMP, 29
benzodiazepine receptors
benzodiazepines
diazepam
GABA
ouabain

Defecation
antidepressants, 969
antihistamines, 979
anxiolytics, 979
benzodiazepine, 979
corticosterone, 979
depression, animal model, 969, 979
haloperidol, 979
imipramine, 969
neuroleptics, 979
open field, 969, 979
oxazepam, 979
stress, 969
tripelennamine, 979
Dependence liability, 725
abstinence syndrome
continuous infusion
narcotics
opiates
Depressants, 449
antidepressants
anxiolytics
depression
electroconvulsive shock
learned helplessness
neuroleptics
stimulants
Depression, 449
antidepressants
anxiolytics
depressants
electroconvulsive shock
learned helplessness
neuroleptics
stimulants
Depression, animal model
antidepressants, 965, 969, 973, 979
antihistamines, 979
anxiolytics, 965, 979
appetite, 965
benzodiazepine, 979
buprion, 973
chronic stress, 965
corticosterone, 979
defecation, 969, 979
haloperidol, 979
hedonic deficit, 965
imipramine, 965, 969
iprindole, 973
mianserine, 973
neuroleptics, 979
open field, 969, 979
oxazepam, 979
plasma corticosterone, 973
stress, 969, 973
tripelennamine, 979
Development
catecholamines, 441
convulsions, tonic, 441
electroshock, 441
haloperidol, 761
monoamines, 441
operant conditioning, 761
postnatal treatment, 761
serotonin, 441
spontaneous activity, 761
Developmental psychopharmacology, 805
avoidance training
cholinergic system
response latency
scopolamine
Dexamethasone, 403
adrenalectomy
analgesia
pain
stress
Diazepam
analgesia, 1005
benzodiazepines, 29
chlordiazepoxide, 795
p-chloroamphetamine, 957
p-chlorophenylalanine, 957
CL218,872, 795
conflict, 795
cyclic GMP, 29
dopaminergic mechanisms, 957
drug interaction, 1005
GABA, 29
haloperidol, 957
hippocampus, 17
hypothalamus, 17
ligand binding, 245
meperidine, 1005
multicomponent receptor, 245
normeperidine, 1005
ouabain, 29
pemoline, 957
pentobarbital, 795
photoaffinity labeling, 245
pimozide, 957
proconvulsive effects, 1005
propyl-β-carboline-3-carboxylate, 245
self-biting, 957
self-stimulation, 17, 795
shuttlebox, 795
sparing from inactivation, 245
Diazepam binding
antileptazol, 529
anxiolytics, 529
benzodiazepine receptors, 29, 245, 529
camazepam, 529
clobazam, 529
oxazepam, 529
temazepam, 529
^{3}H-Diazepam binding
benzodiazepine receptors, 373
brain, ovine, 373
triazolopyridazine CL218,872, 373
Dietary self-selection
amphetamine, 303
anorexia, 303
caloric intake, 303
caloric intake patterns, 949
carbohydrate, 303, 949
eating, 303, 949

β-endorphin, 949
fat, 303, 949
fenfluramine, 303
morphine, 949
protein, 303, 949
Dietary tyrosine, 73
aggressive behavior
brain monoamines
fusarci acid
mice
motor activity
5-α-Dihydrotestosterone, 211
estrogen
lesions, electrolytic
lesions, 6-OHDA
lesions, septal nuclei
lordosis
mesolimbic dopamine pathway
ovariectomy
sexual behavior, female rat
Dihydroxyphenylacetic acid, 131
brain perfusion
endogenous dopamine metabolites
HPLC
homovanillic acid
5-hydroxyindoleacetic acid
2,5-Dimethoxy-4-methylphenylisopropylamine (DOM)
discriminative stimulus properties, 553, 557
2,5-DMA, 553
DOM homologs, 557
DOM molecular modifications, 553
hallucinogens, 553, 557
2,5-Dimethoxyphenylisopropylamine (2,5-DMA), 553
discriminative stimulus properties
DOM
DOM molecular modification
hallucinogens
Diphenhydramine, 591
histamine levels
histidine decarboxylase
plasma corticosterone
stress
Discriminative stimulus properties
2,5-DMA, 553
DOM, 553, 557
DOM homologs, 557
DOM molecular modifications, 553
hallucinogens, 553, 557
DNA synthesis, 185
abrin
human peripheral lymphocytes
protein synthesis
virus transformed lymphocytes
DOM homologs, 557
discriminative stimulus properties
DOM
hallucinogens
DOM molecular modifications, 553
discriminative stimulus properties
2,5-DMA
DOM
hallucinogens
Dopamine
acetylcholine, 533
β-adrenoceptor antagonists, 741
alcohol, 321
alcohol preference, rats, 145
antinociception, 47
apomorphine, 859
aspartate, 509
attention, 377
behavioral arousal, 667
biogenic amine metabolites, 641
biogenic monoamine turnover, 641
calcium-sodium ratio, 321
catalepsy, 533
catecholamine interactions, 377
dopamine, 145, 321
extinction, 667, 859
GABA, 509
gerbils, 377
glutamate, 509
gnawing, 407
habituation, 377
HPLC, 641
5-hydroxyindoleacetic acid, 145
hyponeophagia, 741
hypothermia, 321
intrathecal injections, 407
locomotor activity, 377
5-MeODMT, 741
morphine self-administration, 509
multiple schedule, 667
neophobia, 741
neuroleptics, 533
neurotransmitter turnover rates, 509
norepinephrine, 47, 145, 321, 377, 509, 641
one compartment electrochemical detector cell, 641
operant responding, 667
opiate reinforcement systems, 509
pimozide, 667
poikilothermia, 321
postnatal development, 533
regional brain monoamines, 145
reinforcement, 667
self-stimulation, 859
serotonin (5-HT), 47, 145, 407, 509, 641, 741
sex differences, 377
stereotypy, 859
stress, 47
successive discrimination, 667
tail-flick, 47
tail-pinch, 407
temperature set-point, 321
thermoregulation, 321
Dopamine depletion, 151
environmental differences
hyperactivity
neonatal catecholamines
norepinephrine depletion
Dopamine metabolism, 229
homovanillic acid
MIF-1
norepinephrine metabolism
serotonin metabolism
striatum
tyrosine hydroxylase
Dopamine receptors
estrogen, 285
estrous cycle, female rat, 285
hypersensitivity, 119
locomotor activity, 119
mesolimbic area, 119
neuroleptics, 119
opiates, 119
rotational behavior, 437
^{3}H-spiroperidol binding, 119
stereotyped behavior, 119, 285, 437
striatum, 119, 285
Dopamine receptor blockade, 67
extinction
pimozide
sensory-motor conditioning hypothesis
Dopamine theory of reward, 293
finickiness
hyperphagia
lesion, hypothalamic
licking behavior
pimozide
quinine

sweet reward
Dopaminergic agonists, 235
apomorphine
stereotypy
striatal dopamine receptors
Dopaminergic mechanisms, 957
p-chloroamphetamine
p-chlorophenylalanine
diazepam
haloperidol
pemoline
pimozide
self-injury
Dopaminergic supersensitivity, 1
amphetamine
animal models, hyperactivity
hyperactivity, haloperidol-induced
lithium
methylphenidate
neonatal rats
Dopaminergic system
aggression, 547
appetite, 701
bombesin, 701
bromergocryptine, 701
cholecystokinin octapeptide, 701
contralateral turning behavior, 7
dorsal raphe lesion, 7
dynorphin, 701
eating, 701
5-HT receptor, 7
lesions, 6-OHDA, 547
mesocorticolimbic system, 547
5-methoxy-N,N-dimethyltryptamine, 7
muricide, 547
opiates, 701
satiety, 701
thyrotropin-releasing hormone, 701
ventral mesencephalic tegmental area (nucleus A10), 547
Dorsal periaqueductal gray, 397
bicuculline
electrical stimulation
flight behavior
GABA mediation
picrotoxin
tranquilizers
Dorsal raphe lesion, 7
contralateral turning behavior
dopaminergic system
5-HT receptor
5-methoxy-N,N-dimethyltryptamine
Dorsal tegmentum, 433
amphetamine
naloxone
prefrontal cortex
reward
self-stimulation
Drinking
alcohol, 707, 827
alcohol preference, 501
amine-aldehyde condensation product, 827
angiotensin II, 87
appetite, 909
central reward mechanisms, 1013
chronic ethanol intake, 155
concurrent schedules, 113, 393
drug concentration, 113
drug interaction, 707
drug self-administration, oral, 113
eating, 909, 1013
endorphins, 173
ethanol, 393
fixed ratio schedules, 113
free-choice alcohol consumption, 501
hyperosmolarity, 87
hypovolemia, 87
Maudsley rats, 707
morphine, 707
naloxone, 87, 173, 827, 1013
naltrexone, 909, 1013
operant behavior, 1013
opiate antagonists, 1013
opiate receptors, 827
opioids, 87
overdrinking, 155
pentobarbital reinforcement, 113
physical dependence, 501
reinforcement, 393
relative responding, 393
renal electrolyte excretion, 909
renal water excretion, 909
rhesus monkeys, 113
salsolinol, 827
schedule-induced polydipsia, 155
selective breeding, 501, 707
strain differences, 707
tetrahydropapaveroline, 827
water exchange, 909
water intake, 113
withdrawal, 501
Drug
abrin, 185
alcohol, 253, 321, 707, 827
amitryptyline, 449
amphetamine, 1, 217, 235, 303, 417, 449, 565, 621, 631
d-amphetamine, 433, 491, 791, 875
l-amphetamine, 433, 875
anisomycin, 463
antiganglioside serum, 611
antileptazol, 529
apomorphine, 47, 119, 131, 235, 377, 437, 859, 875
arecoline, 677
atenolol, 741
atropine, 533
atropine methylnitrate, 423
atropine sulfate, 423
barbital, 467
BC105, 47
benactyzine, 605
benzodiazepine, 373, 529, 689, 979
bicuculline, 225, 397
bromergocryptine, 701
bupropion, 791, 973
butaclamol, 321
butorphanol, 167
caffeine, 449, 745
camazepam, 529
capsaicin, 241
carbachol, 397
propyl-β-carboline-3-carboxylate, 245
chlordiazepoxide, 279, 397, 449, 689, 795
β-chlornaltrexamine, 621
p-chloroamphetamine, 441, 881, 957
p-chlorophenylalanine, 777, 957
chloroprocaine, 491
chlorpromazine, 411, 449, 541, 615
choleragenoid, 611
cinanserin, 7, 51
CL218,872, 795
clobazam, 529
clonidine, 47, 377, 731, 785
clorgyline, 429
clozapine, 533, 785
cocaine, 347, 359, 491, 631, 661, 713, 855
codeine, 851
corticosterone, 979
cyproheptadine, 7
desipramine, 449, 881
desmethylimipramine, 377
dexamethasone, 403, 585

dextrorphan, 263
diazepam, 17, 29, 245, 329, 449, 529, 795, 957, 1005
^{3}H-diazepam, 373
L-dihydroxyphenylalanine, 441
5,7-dihydroxytryptamine, 441
dimethocaine, 491
dimethylaminoethanol (Deanol), 491
dimethylprocaine, 491
diphenhydramine, 591
2,5-DMA, 553
DOM, 553, 557
doxepin, 449
DSP-4, 197
dynorphin, 897
D-Ala^2, D-Leu^5-enkephalin, 249
ethanol, 13, 35, 63, 125, 155, 181, 207, 321, 341, 393, 449, 473, 501, 585, 693, 719, 757, 903, 995
ethylketocyclazocine, 249
fenfluramine, 303
fentanyl, 249
fluoxetine, 881
β-fumarate methyl naltrexone, 621
fusaric acid, 73
d,l-glaucine·1.5 phosphate, 851
2-deoxy-D-glucose, 411
haloperidol, 1, 7, 47, 131, 311, 407, 411, 449, 541, 701, 761, 769, 785, 957, 979
histidyl-proline diketopiperazine, 225
γ-hydroxybutyrate, 235
6-hydroxydopamine, 151, 441, 455, 615
5-hydroxytryptophan, 441, 777
hyoscine, 7
imipramine, 449, 965, 969
iprindole, 449, 973
iproniazid, 449
isoproterenol, 627
LSD, 51, 63
lead acetate, 631
levorphanol, 263
lisuride hydrogen maleate, 437
lithium, 1
lithium chloride, 801
lorazepam, 449
marijuana, 573
meperidine, 1005
mescaline, 63
metergoline, 881
methadone, 81, 119, 271, 569
methaqualone, 925
methiothepin, 481
methocarbamol, 785
5-methoxy N,N,dimethyltryptamine (5-MeODMT), 7, 741
3-methoxy-4-hydroxyphenylethyleneglycol sulfate (MHPG-SO_4), 637
α-methyl-p-tyrosine, 7, 235
methylphenidate, 1, 417
methysergide, 7, 203, 321, 407, 481, 731, 741
metoclopramide, 785
mianserin, 449, 973
morphine, 35, 81, 119, 167, 263, 411, 473, 487, 509, 611, 621, 683, 707, 725, 751, 869, 949, 983
muscimol, 897
nalbuphine, 167
naloxone, 7, 35, 87, 173, 225, 263, 407, 433, 473, 487, 561, 599, 653, 701, 725, 751, 827, 989, 1001, 1013
naltrexone, 561, 653, 751, 909, 1013
nicotine, 677
nitromifene citrate (CI-628), 93
norepinephrine, 101, 225, 897
normeperidine, 1005
nortryptyline, 449
5-OH-5-ethyl-5-phenyl-butiramide, 177
6-OHDA, 547
ouabain, 29
oxazepam, 529, 979
oxotremorine, 677
pargyline, 131, 449
pemoline, 957
pentazocine, 167, 983
pentobarbital, 63, 113, 159, 271, 397, 487, 579, 661, 795, 815
phencyclidine, 159, 647, 847, 937, 1009
phenobarbital, 449, 737
phenoxybenzamine, 47, 615
phentolamine, 321, 481, 731
phenytoin, 843
picrotoxin, 7, 397, 737
pimozide, 67, 293, 667, 975
pindolol, 741
piperocaine, 491
pipradrol, 791
prazosin, 615, 785
probenecid, 131
procainamide, 491
procaine, 491
profadol, 487
propoxycaine, 491
propranolol, 481, 471
proteo-N,N-dimethyltryptamine, 811
pyridoxine, 361
quinine, 293
quipazine, 47, 481
reserpine, 731
Ro 5-3663, 689
RX 336-M, 929
salsolinol, 827
scopolamine, 481, 677, 805, 919
serotonin, 51, 407
SKF-7265, 731
spiroperidol, 533
strychnine, 7, 397
sulpiride, 437, 653
temazepam, 529
tetrabenazine, 441
tetradentero-N,N-dimethyltryptamine, 811
Δ^8-tetrahydrocannabinol, 573
Δ^9-tetrahydrocannabinol, 573
tetrahydropapaveroline, 827, 995
thyroxine, 203
triazolopyridazine, CL218,872, 373
tripelennamine, 979
l-tryptophan, 51, 131
L-tyrosine, 73
xylamidine, 7
yohimbine, 615, 731
zimelidine, 881
Drug administration, chronic, 467
  active avoidance
  anxiety
  anxiolytics
  barbital
  barbiturates
  brain drug levels
  righting reflex
  tolerance
Drug administration, "lifetime", 429
  clorgyline
  drug administration, subacute
  monoamine oxidase
  REM sleep
  sleep stages
Drug administration, subacute, 429
  clorgyline
  drug administration, "lifetime"
  monoamine oxidase
  REM sleep
  sleep stages
Drug concentration, 113
  concurrent schedules
  drinking
  drug self-administration, oral

fixed ratio schedules
pentobarbital reinforcement
rhesus monkeys
water intake
Drug discrimination
anesthetics, local, 491
D-Ala², D-Leu⁵-enkephalin, 249
ethylketocyclazocine, 249
fentanyl, 249
multiple opiate receptors, 249
narcotics, 249
reinforcement, 491
self-administration, 491
species differences, 491
Drug interactions
activity, 411
acute drug pretreatment, 847
alcohol, 707
amine-aldehyde metabolites, 995
analgesia, 1005
chained schedule, 271
chronic drug pretreatment, 847
cold water swims, 411
diazepam, 1005
drinking, 707
ethanol, 847
ethanol self-selection, 995
ethanol sensitivity, 473
fixed interval, 271
hypothermia, 473
macaque monkey, female, 995
Maudsley rats, 707
meperidine, 1005
methadone, 271
morphine, 473, 707
multiple schedule, 159
neuroleptics, 411
normeperidine, 1005
operant behavior, 159
opiate analgesia, 411
opiates, 473
pain, 411
patas monkeys, 159
pentobarbital, 159, 271
pharmacogenetics, 473
phencyclidine, 159, 847
pigeons, 271
preconvulsive effects, 1005
response chains, 159
route of delivery, 995
selective breeding, 473, 707
strain difference, 707
supra-additive effects, 159
tetrahydropapaveroline, ICV infusion, 995
Drug self-administration
butorphanol, 167
concurrent schedules, 113
drinking, 113
drug concentration, 113
ethanol, 181
fixed ratio schedules, 113
morphine-dependent rats, 167
nalbuphine, 167
pentazocine, 167
pentobarbital reinforcement, 113
physical dependence, 167
reward, 181
rhesus monkeys, 113
water intake, 113
DSP-4, 197
noradrenaline
operant behavior
positive reinforcement
Dynorphin, 701
appetite
bombesin
bromergocryptine
cholecystokinin octapeptide
dopaminergic system
eating
opiates
satiety
thyrotropin-releasing hormone

Eating
amphetamine, 303
anorexia, 303
appetite, 225, 303, 909
bicuculline, 225
body weight, 933
bombesin, 225, 701
bromergocryptine, 701
calcitonin, 225
caloric intake, 303
caloric intake patterns, 949
carbohydrate, 303, 949
central reward mechanisms 1013
cholecystokinin octapeptide, 225, 701
dietary self-selection, 303, 949
dopaminergic system, 701
drinking, 909, 1013
dynorphin, 701
β-endorphin, 949
estrogen and food intake, 93
fat, 303, 949
fenfluramine, 303
food deprivation, 579
histidyl-proline diketopiperazine, 225
hypoglycemia, 1001
hypothalamic hyperphagia, 101
insulin-induced feeding, 1001
knife cuts, hypothalamus, 101
morphine, 949
naloxone, 225, 1001, 1013
naltrexone, 909, 1013
nitromifene citrate (CI-628), 93
noradrenergic feeding, 101
norepinephrine, 101
norepinephrine-induced feeding, 225
novel environment, 1001
obesity, 101
operant behavior, 1013
opiate antagonists, 1013
opiates, 701
pentobarbital, 579
prepubertal male rat, 933
protein, 303, 949
renal electrolyte excretion, 909
renal water excretion, 909
rhesus monkeys, 579
satiety, 579, 701, 897
self-administration, oral, 579
somatostatin, 897
testosterone, 933
thyrotropin releasing hormone, 225, 701
vagus nerve, 897
ventromedial hypothalamus, 93
water exchange, 909
Electrical stimulation, 397
bicuculline
dorsal periaqueductal gray
flight behavior
GABA mediation
picrotoxin
tranquilizers
Electrocortical afterdischarges, 177
anticonvulsants
convulsions, drug-induced
convulsions, electroshock-induced

5-OH-5-ethyl-5-phenyl-butiramide
Electroconvulsive shock, 455
antidepressants
anxiolytics
depressants
depression
learned helplessness
neuroleptics
stimulants
Electroshock, 441
catecholamines
convulsions, tonic
development
monoamines
serotonin
Emotionality, 769
haloperidol
hyperirritability
lesions, septal
recovery of function
septal rage
Endogenous dopamine metabolites, 131
brain perfusion
dihydroxyphenylacetic acid
homovanillic acid
HPLC
5-hydroxyindoleacetic acid
β-Endorphin, 949
caloric intake patterns
carbohydrate
dietary self-selection
eating
fat
morphine
protein
Endorphins
drinking, 173
naloxone, 173, 599
respiration, 599
stress, 599
D-Ala^2,D-Leu^5-enkephalin, 249
drug discrimination
ethylketocyclazocine
fentanyl
multiple opiate receptors
narcotics
Environmental differences, 151
dopamine depletion
hyperactivity
neonatal catecholamines
norepinephrine depletion
Estrogen
amphetamine, 875
apomorphine, 875
5α-dihydrotestosterone, 211
dopamine receptors, 285
estrous cycle, female rat, 285
lesions, electrolytic, 211
lesions, 6-OHDA, 211
lesions, septal nuclei, 211
lordosis, 211
mesolimbic dopamine pathway, 211
ovariectomy, 211
progesterone, 875
sexual behavior, female rat, 211, 875
sterotyped behavior, 875
stereotypy, 285
striatum, 285
Estrogen and food intake, 93
eating
nitromifene citrate (CI-628)
ventromedial hypothalamus
Estrogen receptors, 837
androgen receptors
5α-androstane-3β,17β-diol
hypothalamic cytosol
lordosis
mounting behavior
ovariectomy
sexual behavior, female rat
Estrous cycle, female rat, 285
dopamine receptors
estrogen
stereotypy
striatum
Ethanol
acute drug pretreatment, 847
adrenal medulla, 719
alcohol, 321
ambient temperature, 903
blood glucose levels, 903
body temperature, 903
calcium-sodium ratio, 321
cardiac mass, 207
catecholamines, 719
chronic drug pretreatment, 847
concurrent schedules, 393
drinking, 393
dopamine, 321
drug interaction, 847
drug self-administration, 181
hypothermia, 321, 903
mitochondrial function, 207
norepinephrine, 321
phencyclidine, 847
physical dependence, 719
poikilothermia, 321
reinforcement, 393
relative responding, 393
reward, 181
serotonin (5-HT), 321
swimming, 207
temperature set-point, 321
thermoregulation, 321
tolerance, 903
withdrawal syndrome, 719
Ethanol antagonists, 341
body temperature
brain-blood ethanol
ethanol metabolism
ethanol narcosis
hyperbaric pressure
Ethanol concentration and distribution, 125
alcohol preference
ethanol sensitivity
selective breeding
Ethanol dependence, 757
chronic treatment
ethanol elimination rates
gender differences
Ethanol elimination rates, 757
chronic treatment
ethanol dependence
gender differences
Ethanol intoxication, 13
ethanol sensitivity
genotypic responses
inbred mice
Ethanol metabolism, 341
body temperature
brain-blood ethanol
ethanol antagonists
ethanol narcosis
hyperbaric pressure
Ethanol narcosis, 341
body temperature
brain-blood ethanol
ethanol antagonists
ethanol metabolism
hyperbaric pressure

Ethanol self-selection, 995
amine-aldehyde metabolites
drug interaction
macaque monkey, female
route of delivery
tetrahydropapaveroline, ICV infusion
Ethanol sensitivity
alcohol-opiate commonalities, 35
alcohol preference, 125
drug interactions, 473
ethanol concentration and distribution, 125
ethanol intoxication, 13
genotypic responses, 13
hypothermia, 473
inbred mice, 13
morphine, 473
morphine withdrawal, 35
opiates, 473
opiate dependence, 35
pharmacogenetics, 473
selective breeding, 35, 473
Ethylketocyclazocine, 249
drug discrimination
D-Ala², D-Leu⁵-enkephalin
fentanyl
multiple opiate receptors
narcotics
Exploratory behavior, 937
autoshaping
phencyclidine
Extrapyramidal effects,731
alpha adrenergic antagonists
alpha-2 receptors
autonomic responses
motor responses
reserpine rigidity
Extinction
acquisition, 943
apomorphine, 859
avoidance, 943
behavioral arousal, 667
chlordiazepoxide, 279
dopamine, 667, 859
dopamine receptor blockade, 67
6-hydroxydopamine, neonatal, 279
intertrial response, 943
multiple schedule, 667
norepinephrine depletion, 279
operant responding, 667
pimozide, 67, 667
punishment-conflict, 279
reinforcement, 667
self-stimulation, 859
sensory-motor conditioning hypothesis, 67
shuttlebox, 943
stereotypy, 859
successive discrimination, 667
TRH, 943

Fat
amphetamine, 303
anorexia, 303
caloric intake, 303, 949
carbohydrate, 303, 949
dietary self-selection, 303, 949
eating, 303, 949
β-endorphin, 949
fenfluramine, 303
morphine, 949
protein, 303, 949
Fenfluramine, 303
amphetamine
anorexia
caloric intake
carbohydrate
dietary self-selection
eating
fat
protein
Fentanyl, 249
D-Ala², D-Leu⁵-enkephalin
drug discrimination
ethylketocyclazocine
multiple opiate receptors
narcotics
Ferret, 677
arecoline
central cholinergic mechanisms
nicotine
oxotremorine
predatory behavior
scopolamine
Fetal ethanol, 585
corticosterone
hypothalamic-pituitary-adrenal system
prenatal ethanol
stress
Finickiness, 293
dopamine theory of reward
hyperphagia
lesions, hypothalamic
licking behavior
pimozide
quinine
sweet reward
Fixed interval
chained schedule, 271
drug interactions, 271
methadone, 271
morphine, 683
pentobarbital, 271
pigeons, 271, 683
schedule-induced escape, 683
Fixed-ratio schedule
anticonvulsant drugs, 843
behavioral tolerance, 647
cerebral cortex, 647
concurrent schedule, 113
drinking, 113
drug concentration, 113
drug self-administration, oral, 113
neurotransmitter receptor binding, 647
pentobarbital reinforcement, 113
phencyclidine, 647
phenytoin, 843
pigeons, 843
rhesus monkeys, 113
tolerance, 843
water intake, 113
FK 33-824, 989
hyperthermia
naloxone
opioid peptides
opioid receptors
thermoregulation
Flight behavior, 397
bicuculline
dorsal periaqueductal gray
electrical stimulation
GABA mediation
picrotoxin
tranquilizers
Food deprivation
aldosterone, 697
angiotensin II, 697
eating, 579
hypovolemia, 697
pentobarbital, 579

plasma osmolality, 697
rhesus monkeys, 579
satiety, 579
self-administration, 579
sodium retention, 697
Footshock
aggression, 63
ataxia, 63
brain region differences, 637
hallucinogens, 63
MHPG-SO_4, 637
noradrenaline turnover, 637
stress, 637
Free-choice alcohol consumption, 501
alcohol preference
drinking
physical dependence
selective breeding
withdrawal
Fusaric acid, 73
aggressive behavior
brain monoamines
dietary tyrosine
mice
motor activity

GABA
aggressive behavior, 57
anxiety, 329, 689
aspartate, 509
barbiturates, 737
benzodiazepine receptors, 29
benzodiazepines, 29
chlordiazepoxide, 689
conditioned emotional response, 329
convulsant benzodiazepine, 689
cyclic GMP, 29
diazepam, 29
dopamine, 509
glutamate, 509
inbred mouse strains, 57
isolation, 57
morphine self-administration, 509
neurotransmitter metabolism, 329
neurotransmitter turnover rates, 509
norepinephrine, 509
opiate reinforcement systems, 509
ouabain, 29
phenobarbital, 737
Ro 5-3663, 689
rotation, 737
serotonin, 509
shock history, 329
substantia nigra, 737
stress, 329
GABA mediation, 397
bicuculline
dorsal periaqueductal gray
electrical stimulation
flight behavior
picrotoxin
tranquilizers
Gender differences, 757
chronic treatment
ethanol dependence
ethanol elimination rates
Genotypic responses, 13
ethanol intoxication
ethanol sensitivity
inbred mice
Gerbils, 377
attention
catecholamine interactions
dopamine
habituation
locomotor activity
norepinephrine
sex differences
d,l-Glaucine·1.5 phosphate, 851
abuse potential
rhesus monkeys
self-administration
Glutamate, 509
aspartate
dopamine
GABA
morphine self-administration
neurotransmitter turnover rates
norepinephrine
opiate reinforcement systems
serotonin
GM1 ganglioside, 611
analgesia
antiganglioside serum
choleragenoid
morphine receptors
Gnawing, 407
dopamine
intrathecal injections
serotonin
tail-pinch
Grooming
arousal, 929
homeostasis, 929
morphine withdrawal syndrome, 929
opiate antagonists, 653
plasma hoarmone levels, 653
RX 336-M, 929
social bonding, 653
talapoin monkeys, 653
wet-dog shakes, 929

Habituation, 377
attention
catecholamine interactions
dopamine
gerbils
locomotor activity
norepinephrine
sex differences
Hallucinogens
aggression, 63
ataxia, 63
cats, 51
discriminative stimulus preperties, 553, 557
2,5-DMA, 553
DOM, 557
DOM homologs, 557
DOM molecular modifications, 553
footshock, 63
LSD, 51
serotonin (5-HT), 51
l-tryptophan, 51
visual evoked responses, 51
Haloperidol
antiapomorphine effect, 311
antihistamines, 979
anxiolytics, 979
benzodiazepine, 979
p-chloroamphetamine, 957
p-chlorophenylalanine, 957
chronic administration, 311
circadian rhythm, 311
clonidine, 785
clozapine, 785
corticosterone, 979

defecation, 979
depression, animal model, 979
development, 761
diazepam, 957
dopaminergic mechanisms, 957
emotionality, 769
hyperirritability, 769
lesions, septal, 769
methocarbamol, 785
metoclopramide, 785
neuroleptics, 979
open field, 979
operant conditioning, 761
oxazepam, 979
pemoline, 957
pimozide, 957
postnatal treatment, 761
prazosin, 785
recovery of function, 769
self-injury, 957
self-stimulation, 785
septal rage, 769
shuttlebox, 785
spontaneous activity, 761
tripelennamine, 979
Hedonic deficit, 965
antidepressants
anxiolytics
appetite
chronic stress
depression, animal model
imipramine
High performance liquid chromatography, (HPLC), 131
brain perfusion
dihydroxyphenylacetic acid
endogenous dopamine metabolites
homovanillic acid
5-hydroxyindoleacetic acid
High pressure liquid chromatography (HPLC), 641
biogenic amine metabolites
biogenic monoamine turnover
dopamine
norepinephrine
one compartment electrochemical detector cell
serotonin
Hippocampus
cerebral asymmetry, 915
copper, 915
diazepam, 17
hypothalamus, 17
lateralization, 915
self-stimulation, 17
spatial behavior, 915
zinc, 915
Histamine levels, 591
diphenhydramine
histidine decarboxylase
plasma corticosterone
stress
Histidine decarboxylase, 591
diphenhydramine
histamine levels
plasma corticosterone
stress
Histidyl-proline diketopiperazine, 225
appetite
bicuculline
bombesin
calcitonin
cholecystokinin octapeptide
eating
naloxone
norepinephrine-induced feeding
thyrotropin releasing hormone
5-HT receptor, 7
contralateral turning behavior
dopaminergic system
dorsal raphe lesions
6-hydroxydopamine
medial forebrain bundle lesions
5-methoxy-N,N-dimethyltryptamine
Homeostasis, 929
arousal
grooming
morphine withdrawal syndrome
RX 336-M
wet-dog shakes
Homovanillic acid
brain perfusion, 131
dihydroxyphenylacetic acid, 131
dopamine metabolism, 229
endogenous dopamine metabolites, 131
HPLC, 131
5-hydroxyindoleacetic acid, 131
MIF-1, 229
norepinephrine metabolism, 229
serotonin metabolism, 229
striatum, 229
tyrosine hydroxylase, 229
Hormone
aldosterone, 697
5α-androstane-3β,17β-diol, 837
cortisol, 653
5α-dihydrotestosterone, 211, 837
estradiol, 837
17β-estradiol, 285
estradiol benzoate, 93
estriol, 93
estrogen, 211, 875
estrone, 93
insulin, 1001
luteinizing hormone, 653
progesterone, 875
prolactin, 653
testosterone, 653, 933
testosterone propionate, 41, 565
Human peripheral lymphocytes, 185
abrin
DNA synthesis
protein synthesis
virus transformed lymphocytes
6-Hydroxydopamine, 7
dopaminergic system
5-HT receptor
ipsilateral turning behavior
medial forebrain bundle lesions
5-methoxy-N,N-dimethyltryptamine
6-Hydroxydopamine, neonatal, 279
chlordiazepoxide
extinction
norepinephrine depletion
punishment-conflict
5-Hydroxyindoleacetic acid
alcohol preference, rats, 145
brain perfusion, 131
dihydroxyphenylacetic acid, 131
dopamine, 145
endogenous dopamine metabolites, 131
homovanillic acid, 131
HPLC, 131
norepinephrine, 145
regional brain monoamines, 145
serotonin, 145
5-Hydroxytryptophan, 777
p-chlorophenylalanine
lordosis
noradrenaline
serotonin
sexual behavior, female rat

Hyperactivity
chronic opiate administration, 263
dopamine depletion, 151
environmental differences, 151
hypoactivity, 263
in utero studies, rats, 263
morphine tolerance, 263
neonatal catecholamines, 151
norepinephrine depletion, 151
spontaneous activity, fetal rat, 263
withdrawal, 263
Hyperactivity, haloperidol-induced, 1
amphetamine
animal models, hyperactivity
dopaminergic supersensitivity
lithium
methylphenidate
neonatal rats
Hyperbaric pressure, 341
body temperature
brain-blood ethanol
ethanol antagonists
ethanol metabolism
ethanol narcosis
Hyperirritability, 769
emomotionality
haloperidol
lesions, septal
recovery of function
septal rage
Hyperosmolarity, 87
angiotensin II
drinking
hypovolemia
naloxone
opioids
Hyperphagia, 293
dopamine theory of reward
finickiness
lesions, hypothalamic
licking behavior
pimozide
quinine
sweet reward
Hypersensitivity, 119
dopamine receptors
locomotor activity
mesolimbic area
neuroleptics
opiates
3H-spiroperidol binding
stereotypy
striatum
Hyperthermia, 989
FK 33-824
naloxone
opioid peptides
opioid receptors
thermoregulation
Hypoactivity
ataxia, 801
behavioral toxicology, 801
chronic opiate administration, 263
hyperactivity, 263
in utero studies, rats, 263
lethality, 801
lithium isotopes, 801
morphine tolerance, 263
spontaneous activity, fetal rat, 263
withdrawal, 263
Hypoglycemia, 1001
eating
insulin-induced feeding
naloxone
novel environment
Hyponeophagia, 741
β-adrenoceptor antagonists
dopamine
5-MeODMT
neophobia
serotonin
Hypothalamic cytosol, 837
androgen receptors
5α-androstane-3β,17β-diol
estrogen receptors
lordosis
mounting behavior
ovariectomy
sexual behavior, female rat
Hypothalamic hyperphagia, 101
eating
knife cuts, hypothalamus
noradrenergic feeding
norepinephrine
obesity
Hypothalamic-pituitary-adrenal system, 585
corticosterone
fetal ethanol
prenatal ethanol
stress
Hypothalamic temperature, 23
body temperature
capsaicin
thermoregulation
Hypothalamus
aggression, 41
androgens, 41
diazepam, 17
hippocampus, 17
self-stimulation, 17
Hypothermia
alcohol, 321
ambient temperature, 903
blood glucose levels, 903
body temperature, 903
calcium-sodium ratio, 321
dopamine, 321
drug interactions, 473
ethanol, 321, 473, 903
metabolism, 361
morphine, 473
norepinephrine, 321
opiates, 473
pharmacogenetics, 473
poikilothermia, 321
pyridoxine, 361
selective breeding, 473
serotonin (5-HT), 321
temperature set-point, 321
thermoregulation, 321
tolerance, 903
vitamin B_6, 361
Hypovolemia
aldosterone, 697
angiotensin II, 87, 697
drinking, 87
food deprivation, 697
hyperosmolarity, 87
naloxone, 87
opioids, 87
plasma osmolality, 697
sodium retention, 697

Imipramine
antidepressants, 965, 969
anxiolytics, 965
appetite, 965
chronic stress, 965
defecation, 969

depression, animal model, 965, 969
hedonic deficit, 965
open field, 969
stress, 969
Inbred mouse strains
aggressive behavior, 57
ethanol intoxication, 13
ethanol sensitivity, 13
GABA, 57
genotypic responses, 13
isolation, 57
locomotor activity, 561
naloxone, 561
naltrexone, 561
Insulin-induced feeding, 1001
eating
hypoglycemia
naloxone
novel environment
Integrated plasma sampling, 521
acute venous catheterization
blood sample collection
primates
Intertrial response, 943
acquisition
avoidance
extinction
shuttlebox
TRH
Intrathecal injections, 407
dopamine
gnawing
serotonin
tail-pinch
In utero studies, rats, 263
chronic opiate administration
hyperactivity
hypoactivity
morphine tolerance
spontaneous activity, fetal rat
withdrawal
Iprindole, 973
antidepressants
buprion
depression, animal model
mianserine
plasma corticosterone
stress
Ipsilateral turning behavior, 7
dopaminergic system
5-HT receptor
6-hydroxydopamine
medial forebrain bundle lesions
5-methoxy-N,N-dimethyltryptamine
Isolation
aggressive behavior, 57
catecholamines, 417
GABA, 57
inbred mouse strains, 57
play, 417
psychomotor stimulants, 417
social behavior, 417
Isolation rearing, 841
behavioral efficacy
opiates
receptor binding
Isoproterenol, 627
brown adipose tissue
obesity
thermogenesis
Zucker rats

Kindling, 1009
afterdischarge thresholds
amygdala
phencyclidine
seizures
Kindling, amygdaloid, 751
opiates
seizures
Kindling, olfactory bulb, 855
afterdischarge threshold
cocaine
Kinetic isotope effect, 811
behavior disruption
proteo-N,N-dimethyltryptamine
tetradeutero-N,N-dimethyltryptamine
Knife cuts, hypothalamus, 101
eating
hypothalamic hyperphagia
noradrenergic feeding
norepinephrine
obesity

LSD, 51
cats
hallucinogens
serotonin (5-HT)
l-tryptophan
visual evoked responses
Lateralization, 915
cerebral asymmetry
copper
hippocampus
spatial behavior
zinc
Lead acetate, 631
amphetamine
brain weight
cocaine
mouse genotype
seizures
Learned helplessness, 449
antidepressants
anxiolytics
depressants
depression
electroconvulsive shock
neuroleptics
stimulants
Lesions, 7
contralateral turning
dorsal raphe
6-hydroxydopamine
medial forebrain bundle
5-methoxy-N,N-dimethyltryptamine
Lesions, electrolytic
asymmetry, 455
catecholamines, 455
5α-dihydrotestosterone, 211
estrogen, 211
lesions, nigrostriatal, 455
lesions, 6-OHDA, 211, 455
lesions, septal nuclei, 211
lesions, substantia nigra, 455
lordosis, 211
mesolimbic dopamine pathway, 211
ovariectomy, 211
sensorimotor dysfunction, 455
sensory extinction, 455
sexual behavior, female rat, 211
Lesions, hypothalamic 293
dopamine theory of reward
finickiness
hyperphagia
licking behavior
pimozide
quinine

sweet reward
Lesions, nigrostriatal, 455
asymmetry
catecholamines
lesions, electrolytic
lesions, 6-OHDA
lesions, substantia nigra
sensorimotor dysfunction
sensory extinction
Lesions, 6-OHDA
aggression, 547
asymmetry, 455
catecholamines, 455
5α-dihydrotestosterone, 211
dopaminergic system, 547
estrogen, 211
lesions, electrolytic, 211, 455
lesions, nigraostriatal, 455
lesions, septal nuclei, 211
lesions, substantia nigra, 455
lordosis, 211
mesocorticolimbic system, 547
mesolimbic dopamine pathway, 211
muricide, 547
ovariectomy, 211
sensorimotor dysfunction, 455
sensory extinction, 455
sexual behavior, female rat, 211
ventral mesencephalic tegmental area (nucleus A10), 547
Lesions, septal
5α-dihydrotestosterone, 211
emotionality, 769
estrogen, 211
haloperidol, 769
hyperirritability, 769
lesions, electrolytic, 211
lesions, 6-OHDA, 211
lordosis, 211
mesolimbic dopamine pathway, 211
ovariectomy, 211
recovery of function, 769
septal rage, 769
sexual behavior, female rat, 211
Lesions, substantia nigra, 455
asymmetry
catecholamines
lesions, electrolytic
lesions, nigrostriatal
lesions, 6-OHDA
sensorimotor dysfunction
sensory extinction
Lethality, 801
ataxia
behavioral toxicology
hypoactivity
lithium isotopes
Lever pressing, 423
atropine methylnitrate
atropine sulfate
motor control
rhesus monkey
Licking behavior, 293
dopamine theory of reward
finickiness
hyperphagia
lesions, hypothalamic
pimozide
quinine
sweet reward
Ligand binding, 245
benzodiazepine receptors
diazepam
multicomponent receptor
photoaffinity labeling
propyl-β-carboline-3-carboxylate
sparing from inactivation
Lithium, 1
amphetamine
animal models, hyperactivity
dopaminergic supersensitivity
hyperactivity, haloperidol-induced
methylphenidate
neonatal rats
Lithium isotopes, 801
ataxia
behavioral toxicology
hypoactivity
lethality
Lizards, 1017
MIF-1
sex differences
tonic immobility
Locomotor activity
aggression, 569
attention, 377
catecholamine interactions, 377
dopamine, 377
dopamine receptors, 377
gerbils, 377
habituation, 377
hypersensitivity, 119
inbred strains, mice, 561
mesolimbic area, 119
methadone, 569
methysergide, 203
naloxone, 561
naltrexone, 561
neonates, mice, 203
neuroleptics, 119
norepinephrine, 377
opiates, 119
serotonergic development, 203
sex differences, 377
social behavior, 569
^{3}H-spiroperidol binding, 119
stereotypy, 119
striatum, 119
thyroxine, 203
Lordosis
androgen receptors, 837
5α-androstane-3β,17β-diol, 837
p-chlorophenylalanine, 777
5α-dihydrotestosterone, 211
estrogen, 211
estrogen receptors
5-hydroxytryptophan, 777
hypothalamic cytosol, 837
lesions, electrolytic, 211
lesions, 6-OHDA, 211
lesions, septal nuclei, 211
mesolimbic dopamine pathway, 211
mounting behavior, 837
noradrenaline, 777
ovariectomy, 211, 837
serotonin, 777
sexual behavior, female rat, 211, 777, 837

Macaque monkey, female, 995
amine-aldehyde metabolites
drug interaction
ethanol self-selection
route of delivery
tetrahydropapaveroline, ICV infusion
Marijuana cannabinoids, 573
cobalt epilepsy
REM sleep
seizures, epileptic
tetrahydrocannabinols

Matching-to-sample, 713
cocaine
conditional discrimination
memory
pigeons
tolerance
Maturation, 217
age differences
amphetamine
avoidance
catecholamines
motor activity
Maudsley rats, 707
alcohol
drinking
drug interaction
morphine
selective breeding
strain differences
Medial forebrain bundle lesions, 7
dopaminergic system
5-HT receptor
6-hydroxydopamine
ipsilateral turning behavior
5-methoxy-N,N-dimethyltryptamine
Memory, 713
cocaine
conditional discrimination
matching-to-sample
pigeons
tolerance
Memory retrieval, 463
amnesia
anisomycin
passive avoidance
vasopressin
Memory, spatial, 919
anticholinergic drugs
memory, working
scopolamine
Memory, working, 919
anticholinergic drugs
memory, spatial
scopolamine
Meperidine, 1005
analgesia
diazepam
drug interaction
normeperidine
proconvulsive effects
Mesocorticolimbic system, 547
aggression
dopaminergic system
lesions, 6-OHDA
muricide
ventral mesencephalic tegmental area (nucleus A10)
Mesolimbic area, 119
dopamine receptors
hypersensitivity
locomotor activity
neuroleptics
opiates
^{3}H-spiroperidol binding
stereotypy
striatum
Mesolimbic dopamine pathway, 211
5α-dihydrotestosterone
estrogen
lesions, electrolytic
lesions, 6-OHDA
lesions, septal nuclei
lordosis
ovariectomy
sexual behavior, female rat
Metabolism, 361
hypothermia
pyridoxine
vitamin B_6
Methadone
aggression, 569
chained schedule, 271
drug interactions, 271
fixed interval, 271
locomotor activity, 569
pentobarbital, 271
pigeons, 271
social behavior, 569
Methaqualone, 925
pituitary-adrenal system
plasma corticosterone
sedative-hypnotics
Methocarbamol, 785
clonidine
clozapine
halperidol
metoclopramide
prazosin
self-stimulation
shuttlebox
Method
acute venous catheterization, 521
continuous infusion, 725
HPLC, 131, 641
photoaffinity labeling, 245
5-Methoxy-N,N-dimethyltryptamine (5-MeODMT)
β-adrenoceptor antagonists, 741
contralateral turning behavior, 7
dopamine, 741
dopaminergic system, 7
dorsal raphe lesion, 7
5-HT receptor, 7
6-hydroxydopamine, 7
hyponeophagia, 741
ipsilateral turning behavior, 7
medial forebrain bundle lesions, 7
neophobia, 741
serotonin, 741
3-Methoxy-4-hydroxyphenyletheneglycol sulfate (MHPG-SO_4)
brain region differences, 315, 637
footshock, 637
noradrenaline turnover, 315, 637
plasma corticosterone, 315
stress, 637
stress, immobilization, 315
time-related differences, 315
Methylphenidate, 1
amphetamine
animal models, hyperactivity
dopaminergic supersensitivity
hyperactivity, haloperidol-induced
lithium
neonatal rats
Methysergide, 203
locomotor activity
neonates, mice
serotonergic development
thyroxine
Metoclopramide, 785
clonidine
clozapine
haloperidol
methocarbamol
prazosin
self-stimulation
shuttlebox
Mianserine, 973
antidepressants
buprion
depression, animal model

iprindole
plasma corticosterone
stress
Mice, 73
aggressive behavior
brain monoamines
dietary tyrosine
fusaric acid
motor activity
MIF-I
dopamine metabolism, 229
homovanillic acid, 229
lizards, 1017
norepinephrine metabolism, 229
serotonin metabolism, 229
sex differences, 1017
striatum, 229
tonic immobility, 1017
tyrosine hydroxylase, 229
Milk-induced behavior, 481
mouthing
rat pups
serotonergic agents
Mitochondrial function, 207
cardiac mass
ethanol
swimming
Monoamine oxidase, 429
clorgyline
drug administration, "lifetime"
drug administration, subacute
REM sleep
sleep stages
Monoamines, 441
catecholamines
convulsions, tonic
development
electroshock
serotonin
Morphine
alcohol, 707
analgesia, 869
caloric intake patterns, 949
carbohydrate, 949
dietary self-selection, 949
drinking, 707
drug interaction, 473, 707
eating, 949
β-endorphin, 949
ethanol sensitivity, 473
fat, 949
fixed interval, 683
hypothermia, 473
Maudsley rats, 707
nociceptive stimuli, 869
opiates, 473
pharmacogenetics, 473
pigeons, 683
protein, 949
schedule-induced escape, 683
selective breeding, 473, 707
startle reflex, 869
strain differences, 707
Morphine-dependent rats, 167
butorphanol
drug self-administration
nalbuphine
pentazocine
physical dependence
Morphine-induced behavior suppression, 621
autoshaped behavior
opiate receptor alkylators
Morphine receptors, 611
analgesia
antiganglioside serum
choleragenoid
GM1 ganglioside
Morphine self-administration, 509
aspartate
dopamine
GABA
glutamate
neurotransmitter turnover rates
norepinephrine
opiate reinforcement systems
serotonin
Morphine tolerance, 263
chronic opiate administration
hyperactivity
hypoactivity
in utero studies, rats
spontaneous activity, fetal rat
withdrawal
Morphine withdrawal, 35
alcohol-opiate commonalities
ethanol sensitivity
opiate dependence
Morphine withdrawal syndrome, 929
arousal
grooming
homeostasis
RX 336-M
wet-dog shakes
Motor activity
age differences, 217
aggressive behavior, 73
amphetamine, 217
avoidance, 217
brain monoamines, 73
catecholamines, 217
dietary tyrosine, 73
fusaric acid, 73
maturation, 217
mice, 73
Motor control, 423
atropine methylnitrate
atropine sulfate
lever pressing
rhesus monkey
Motor responses, 731
alpha adrenergic antagonists
alpha-2 receptors
autonomic responses
extrapyramidal effects
reserpine rigidity
Mounting behavior, 837
androgen receptors
5α-androstane-3β,17β-diol
estrogen receptors
hypothalamic cytosol
lordosis
ovariectomy
sexual behavior, female rat
Mouse genotype, 631
amphetamine
brain weight
cocaine
lead acetate
seizures
Mouthing, 481
milk-induced behavior
rat pups
serotonergic agents
Multicomponent receptor, 245
benzodiazepine receptors
diazepam
ligand binding
photoaffinity labeling
propyl-β-carboline-3-carboxylate
sparing from inactivation

Multiple opiate receptors, 249
drug discrimination
D-Ala², D-Leu⁵-enkephalin
ethylketocyclazocine
fentanyl
narcotics
Multiple schedule
behavioral arousal, 667
dopamine, 667
drug interaction, 159
extinction, 667
operant responding, 159, 667
patas monkeys, 159
pentobarbital, 159
phencyclidine, 159
pimozide, 667
reinforcement, 667
response chains, 159
successive discrimination, 667
supra-additive effects, 159
Muricide, 547
aggression
dopaminergic system
lesions, 6-OHDA
mesocorticolimbic system
ventral mesencephalic tegmental area (nucleus A10)

Nalbuphine, 167
butorphanol
drug self-administration
morphine-dependent rats
pentazocine
physical dependence
Naloxone
alcohol, 827
amine-aldehyde condensation product, 827
amphetamine, 433
angiotensin II, 87
appetite, 225
bicuculline, 225
bombesin, 225
calcitonin, 225
central reward mechanisms, 1013
cholecystokinin octapeptide, 225
drinking, 87, 173, 827, 1013
dorsal tegmentum, 433
eating, 225, 1001, 1013
endorphins, 173, 599
FK 33-824, 989
histidyl-proline diketopiperazine, 225
hyperosmolarity, 87
hyperthermia, 989
hypoglycemia, 1001
hypovolemia, 87
inbred strains, mice, 561
insulin-induced feeding, 1001
locomotor activity, 561
naloxone, 989
naltrexone, 561, 1013
norepinephrine-induced feeding, 225
novel environment, 1001
operant behavior, 1013
opiate antagonists, 1013
opiate receptors, 827
opioid peptides, 989
opioid receptors, 989
opioids, 87
prefrontal cortex, 433
respiration, 599
reward, 433
salsolinol, 827
self-stimulation, 433
stress, 599
tetrahydropapaveroline, 827
thermoregulation, 989
thyrotropin releasing hormone, 225
Naltrexone
appetite, 909
central reward mechanisms, 1013
drinking, 909, 1013
eating, 909, 1013
inbred strains, mice, 561
locomotor activity, 561
naloxone, 561, 1013
operant behavior, 1013
opiate antagonists, 1013
renal electrolyte excretion, 909
renal water excretion, 909
water exchange, 909
Narcotics
abstinence syndrome, 725
continuous infusion, 725
dependence liability, 725
drug discrimination, 249
D-Ala²,D-Leu⁵-enkephalin, 249
ethylketocyclazocine, 249
fentanyl, 249
multiple opiate receptors, 249
opiates, 725
Neonatal catecholamines, 151
dopamine depletion
environmental differences
hyperactivity
norepinephrine depletion
Neonatal treatment, 241
analgesia
capsaicin
nociceptive stimuli
Neonatal rats, 1
amphetamine
animal models, hyperactivity
dopaminergic supersensitivity
hyperactivity, haloperidol-induced
lithium
methylphenidate
Neonates, mice, 203
locomotor activity
methysergide
serotonergic development
thyroxine
Neophobia, 741
β-adrenoceptor antagonists
dopamine
hyponeophagia
5-MeODMT
serotonin
Neurohypophyseal hormone analogs, 819
behavioral effects
oxytocin
structure-activity
vasopressin
Neuroleptics
acetylcholine, 533
activity, 411
antidepressants, 449
antihistamines, 979
anxiolytics, 449, 979
avoidance, 541
benzodiazepine, 979
catalepsy, 533
cold water swims, 411
corticosterone, 979
defecation, 979
depressants, 449
depression, 449
depression, animal model, 979
dopamine, 533
dopamine receptors, 119
drug interaction, 411

electroconvulsive shock, 449
haloperidol, 979
hypersensitivity, 119
learned helplessness, 449
locomotor activity, 119
mesolimbic area, 119
opiate analgesia, 411
opiates, 119
open field, 979
oxazepam, 979
pain, 411
postnatal development, 533
reversal learning, 541
spatial preference, 541
^{3}H-spiroperidol binding, 119
stereotypy, 119
stimulants, 449
striatectomy, 541
striatum, 119
tripelennamine, 979
Y-maze performance, 541
Neurotransmitter metabolism, 329
anxiety
conditioned emotional response
GABA
shock history
stress
Neurotransmitter receptor binding, 647
behavioral tolerance
cerebral cortex
fixed-ratio responding
phencyclidine
Neurotransmitter turnover rates, 509
aspartate
dopamine
GABA
glutamate
morphine self-administration
norepinephrine
opiate reinforcement systems
serotonin
Nicotine, 677
arecoline
central cholinergic mechanisms
ferret
oxotremorine
predatory behavior
scopolamine
Nitromifene citrate (CI-628), 93
eating
estrogen and food intake
ventromedial hypothalamus
Nociceptive stimuli
analgesia, 241, 869
capsaicin, 421
morphine, 869
neonatal treatment, 241
startle reflex, 869
Noradrenaline
p-chlorophenylalanine, 777
DSP-4, 197
5-hydroxytryptophan, 777
lordosis, 777
operant behavior, 197
positive reinforcement, 197
serotonin, 777
sexual behavior, female rat, 777
Noradrenaline turnover
brain region differences, 315, 637
footshock, 637
MHPG-SO_4, 315, 637
plasma corticosterone, 315
stress, 637
stress, immobilization, 315
time-related differences, 315
Noradrenergic feeding, 101
eating
hypothalamic hyperphagia
knife cuts, hypothalamus
norepinephrine
obesity
Norepinephrine
alcohol, 319
alcohol preference, rats, 145
antinociception, 47
aspartate, 509
attention, 377
biogenic amine metabolites, 641
biogenic monoamine turnover, 641
calcium-sodium ratio, 319
catecholamine interactions, 377
dopamine, 47, 145, 319, 377, 509, 641
eating, 101
ethanol, 319
GABA, 509
gerbils, 377
glutamate, 509
HPLC, 641
habituation, 377
5-hydroxyindoleacetic acid, 145
hypothalamic hyperphagia, 101
hypothermia, 319
knife cuts, hypothalamus, 101
locomotor activity, 377
morphine self-administration, 509
neurotransmitter turnover rates, 509
noradrenergic feeding, 101
obesity, 101
one compartment electrochemical detector cell, 641
opiate reinforcement systems, 509
poikilothermia, 319
regional brain monoamines, 145
serotonin, 47, 145, 319, 509, 641
sex differences, 377
stress, 47
tail-flick, 47
temperature, set-point, 319
thermoregulation, 319
Norepinephrine depletion
chlordiazepoxide, 279
dopamine depletion, 151
environmental differences, 151
extinction, 279
6-hydroxydopamine, neonatal, 279
hyperactivity, 151
neonatal catecholamines, 151
punishment-conflict, 279
Norepinephrine-induced feeding, 225
appetite
bicuculline
bombesin
calcitonin
cholecystokinin octapeptide
eating
histidyl-proline diketopiperazine
naloxone
thyrotropin releasing hormone
Norepinephrine metabolism, 229
dopamine metabolism
homovanillic acid
MIF-1
serotonin metabolism
striatum
tyrosine hydroxylase
Normeperdine, 1005
analgesia
diazepam
drug interaction
meperidine
proconvulsive effects

Novel environment, 1001
eating
hypoglycemia
insulin-induced feeding
naloxone

Obesity
brown adipose tissue, 627
eating, 101
hypothalamic hyperphagia, 101
isoproterenol, 627
knife cuts, hypothalamus, 101
noradrenergic feeding, 101
norepinephrine, 101
thermogenesis, 627
Zucker rats, 627
5-OH-5-ethyl-5-phenyl-butiramide, 177
anticonvulsants
convulsions, drug-induced
convulsions, electroshock-induced
electrocortical afterdischarges
One compartment electrochemical detector cell, 641
biogenic amine metabolites
biogenic monoamine turnover
dopamine
HPLC
norepinephrine
serotonin
Ontogeny, 615
post-decapitation reflex
spinal cord monoamines
Open field
antidepressants, 969
antihistamines, 979
anxiolytics, 979
benzodiazepine, 979
corticosterone, 979
defecation, 969, 979
depression, animal model, 969, 979
haloperidol, 979
imipramine, 969
neuroleptics, 979
oxazepam, 979
stress, 969
tripelennamine, 979
Operant behavior
benactyzine, 605
central reward mechanisms, 1013
drinking, 1013
drug interaction, 159
DSP-4, 197
eating, 1013
multiple schedule, 159
naloxone, 1013
naltrexone, 1013
noradrenaline, 197
opiate antagonists, 1013
patas monkeys, 159
pentobarbital, 159
phencyclidine, 159
pigeon, 487
positive reinforcement, 197
primate equilibrium platform, 605
profadol, 487
response chains, 159
rhesus monkey, 605
supra-additive effects, 159
Operant conditioning, 761
development
haloperidol
postnatal treatment
spontaneous activity
Operant responding, 667
behavioral arousal
dopamine
extinction
multiple schedule
pimozide
reinforcement
successive discrimination
Opiate analgesia, 411
activity
cold water swims
drug interaction
neuroleptics
pain
Opiate antagonists
central reward mechanisms, 1013
drinking, 1013
grooming, 653
eating, 1013
naloxone, 1013
naltrexone, 1013
operant behavior, 1013
plasma hormone levels, 653
social bonding, 653
talapoin monkeys, 653
Opiate dependence, 35
alcohol-opiate commonalities
ethanol sensitivity
morphine withdrawal
Opiate receptors, 827
alcohol
amine-aldehyde condensation product
drinking
naloxone
salsolinol
tetrahydropapaveroline
Opiate receptor alkylators, 621
autoshaped behavior
morphine-induced behavior suppression
Opiate reinforcement systems, 509
aspartate
dopamine
GABA
glutamate
morphine self-administration
neurotransmitter turnover rates
norepinephrine
serotonin
Opiates
abstinence syndrome, 725
analgesia, 81
appetite, 701
behavioral efficacy, 541
bombesin, 701
bromergocryptine, 701
cholecystokinin octapeptide, 701
continuous infusion, 725
dependence liability, 725
dopamine receptors, 119
dopaminergic system, 701
drug interactions, 473
dynorphin, 701
eating, 701
ethanol sensitivity, 473
hypersensitivity, 119
hypothermia, 473
isolation rearing, 541
kindling, amygdaloid, 751
mesolimbic area, 119
morphine, 473
narcotics, 725
neuroleptics, 119
pharmacogenetics, 473
receptor binding, 541
satiety, 701
seizures, 751
selective breeding, 473

self-stimulation, 81
^{3}H-spiroperidol binding, 119
stereotypy, 119
striatum, 119
thyrotropin-releasing hormone, 701
Opioid peptides
FK 33-824, 989
hyperthermia, 989
naloxone, 989
opioid receptors, 989
opioids, 983
route of delivery, 983
thermoregulation, 983, 989
Opioid receptors, 989
FK 33-824
hyperthermia
naloxone
opioid peptides
thermoregulation
Opioids
angiotensin II, 87
drinking, 87
hyperosmolarity, 87
hypovolemia, 87
naloxone, 87
opioid peptides, 983
route of delivery, 983
thermoregulatory behavior, 983
ORG 2766, potency and duration, 387
$ACTH_{4-10}$
active avoidance
[D-Phe^7]$ACTH_{4-10}$, potency and duration
passive avoidance
Ouabain, 29
benzodiazepine receptors
benzodiazepines
cyclic GMP
diazepam
GABA
Ovariectomy
amphetamine, 565
androgen receptors, 837
5α-androstane-3β,17β-diol, 837
castration, 565
5α-dihydrotestosterone, 211
estrogen, 211
estrogen receptors, 837
hypothalamic cytosol, 837
lesions, electrolytic, 211
lesions, 6-OHDA, 211
lesions, septal nuclei, 211
lordosis, 211, 837
mesolimbic dopamine pathway, 211
mounting behavior, 837
sex differences, 565
sexual behavior, female rat, 211, 837
stereotyped behavior, 565
Overdrinking, 155
chronic ethanol intake
drinking
schedule-induced polydipsia
Oxazepam
antihistamines, 979
antileptazol, 529
anxiolytics, 529, 979
benzodiazepine, 979
benzodiazepine receptors, 529
camazepam, 529
clobazam, 529
corticosterone, 979
defecation, 979
depression, animal model, 979
diazepam binding, 529
haloperidol, 979
neuroleptics, 979
open field, 979
temazepam, 529
tripelennamine, 979
Oxotremorine, 677
arecoline
central cholinergic mechanisms
ferret
nicotine
predatory behavior
scopolamine
Oxytocin, 819
behavioral effects
neurohypophyseal hormone analogs
structure-activity
vasopressin

Pain
activity, 411
adrenalectomy, 403
analgesia, 403
cold water swims, 411
dexamethasone, 403
drug interaction, 411
neuroleptics, 411
opiate analgesia, 411
stress, 403
Passive avoidance
$ACTH_{4-10}$, 387
active avoidance, 387
amnesia, 463
anisomycin, 463
[D-Phe^7]$ACTH_{4-10}$, potency and duration, 387
memory retrieval, 463
ORG 2766, potency and duration, 387
vasopressin, 463
Patas monkeys, 159
drug interaction
multiple schedule
operant behavior
pentobarbital
phencyclidine
response chains
supra-additive effects
Pavlovian conditioning, 661
cocaine
conditional drug states
cross-potentiation
pentobarbital
tolerance
Pemoline, 957
p-chloroamphetamine
p-chlorophenylalanine
diazepam
dopaminergic mechanisms
haloperidol
pimozide
self-injury
Pentazocine, 167
butorphanol
drug self-administration
morphine-dependent rats
nalbuphine
physical dependence
Pentobarbital
albinism, 815
chained schedule, 271
chlordiazepoxide, 795
CL218,872, 795
cocaine, 661
conditional drug states, 661
conflict, 795
cross-potentiation, 661
diazepam, 795
drug interaction, 159, 271

eating, 579
fixed interval, 271
food deprivation, 579
methadone, 271
multiple schedule, 159
operant behavior, 159
patas monkeys, 159
Pavlovian conditioning, 661
phencyclidine, 159
pigeons, 271
response chains, 159
response duration, 815
rhesus monkeys, 579
satiety, 579
self-administration, oral
self-stimulation, 795
sex differences, 815
shuttlebox, 795
supra-additive effects, 159
tolerance, 661
Pentobarbital reinforcement, 113
concurrent schedules
drinking
drug concentration
drug self-administration, oral
fixed ratio schedules
rhesus monkeys
water intake
Peptide
$ACTH_{4-10}$, 387
[D-Phe^7]$ACTH_{4-10}$, 387
D-Ala^2-Met-enkephalinamide, 983
D-Ala^2-D-Leu-enkephalin, 983
angiotensin II, 87, 697
bombesin, 225, 701
calcitonin, 225
CCK-8, 225
cholecystokinin octapeptide, 701
dynorphin, 701
β-endorphin, 949
FK 33-824, 989
MIF-I, 229, 1017
ORG 2766, 387
oxytocin, 819
somatostatin, 897
thyrotropin-releasing hormone (TRH), 225, 701, 943
vasopressin, 139, 463, 819
Pharmacogenetics, 473
drug interactions
ethanol sensitivity
hypothermia
morphine
opiates
selective breeding
Phencyclidine
acute drug pretreatment, 847
afterdischarge thresholds, 1009
amygdala, 1009
autoshaping, 937
behavioral tolerance, 647
cerebral cortex, 647
chronic drug pretreatment, 847
drug interaction, 159, 847
ethanol, 847
exploratory behavior, 937
fixed-ratio responding, 647
kindling, 1009
multiple schedule, 159
neurotransmitter receptor binding, 647
operant behavior, 159
patas monkeys, 159
pentobarbital, 159
response chains, 159
seizures, 1009
supra-additive effects, 159
Phenobarbital, 737
barbiturates
GABA
rotation
substantia nigra
Phenytoin, 843
anticonvulsant drugs
fixed-ratio schedule
pigeons
tolerance
Photoaffinity labeling, 245
benzodiazepine receptors
diazepam
ligand binding
multicomponent receptor
propyl-β-carboline-3-carboxylate
sparing from inactivation
Physical dependence
adrenal medulla, 719
alcohol preference, 501
butorphanol, 167
catecholamines, 719
drinking, 501
drug self-administration, 167
ethanol, 719
free-choice alcohol consumption, 501
morphine-dependent rats, 167
nalbuphine, 167
pentazocine, 167
selective breeding, 501
withdrawal syndrome, 501, 719
Picrotoxin, 397
bicuculline
dorsal periaqueductal gray
electrical stimulation
flight behavior
GABA mediation
tranquilizers
Pigeons
anticonvulsant drugs, 843
chained schedule, 271
cocaine, 713
conditional stimulation, 713
drug interactions, 271
fixed interval schedule, 271, 683, 843
matching-to-sample, 713
memory, 713
methadone, 271
morphine, 683
operant behavior, 487
pentobarbital, 271
phenytoin, 843
profadol, 487
schedule-induced escape, 683
tolerance, 713, 843
Pimozide
behavioral arousal, 667
p-chloroamphetamine, 957
p-chlorophenylalanine, 957
diazepam, 957
dopamine, 667
dopamine receptor blockade, 67
dopamine theory of reward, 293
dopaminergic mechanisms, 957
extinction, 67, 667
finickiness, 293
haloperidol, 957
hyperphagia, 293
lesions, hypothalamic, 293
licking behavior, 293
multiple schedule, 667
operant responding, 667
pemoline, 957
quinine, 293
reinforcement, 667

self-injury, 957
sensory-motor conditioning hypothesis, 67
successive discrimination, 667
sweet reward, 293
Pipradrol, 791
d-amphetamine
bupropion
self-stimulation
Pituitary-adrenal system, 925
methaqualone
plasma corticosterone
sedative-hypnotics
Plasma corticosterone
antidepressants, 973
brain, regional differences, 315
buprion, 973
depression, animal model, 973
diphenhydramine, 591
histamine levels, 591
histidine decarboxylase, 591
iprindole, 973
methaqualone, 925
MHPG-SO_4, 315
mianserine, 973
noradrenaline turnover, 315
pituitary-adrenal system, 925
sedative-hypnotics, 925
stress, 591, 973
stress, immobilization, 315
time-related differences, 315
Plasma hormone levels, 653
grooming
opiate antagonists
social bonding
talapoin monkeys
Plasma osmolality, 697
aldosterone
angiotensin II
food deprivation
hypovolemia
sodium retention
Play, 417
catecholamines
isolation
psychomotor stimulants
social behavior
Poikilothermia, 321
alcohol
calcium-sodium ratio
dopamine
ethanol
hypothermia
norepinephrine
serotonin (5-HT)
temperature set-point
thermoregulation
Positive reinforcement, 197
DSP-4
noradrenaline
operant behavior
Post-decapitation reflex, 615
ontogeny
spinal cord monoamines
Postnatal development, 533
acetylcholine
catalepsy
dopamine
neuroleptics
Postnatal treatment, 761
development
haloperidol
operant conditioning
spontaneous activity
Prazosin, 785
clonidine
clozapine
haloperidol
methocarbamol
metoclopramide
self-stimulation
shuttlebox
Predatory behavior, 677
arecoline
central cholinergic mechanisms
ferret
nicotine
oxotremorine
scopolamine
Prefrontal cortex, 433
amphetamine
dorsal tegmentum
naloxone
reward
self-stimulation
Prenatal ethanol, 585
corticosterone
fetal ethanol
hypothalamic-pituitary-adrenal system
stress
Prepubertal male rat, 933
body weight
eating
testosterone
Primates, 521
acute venous catheterization
blood sample collection
integrated plasma sampling
Primate equilibrium platform, 605
benactyzine
operant behavior
rhesus monkey
Proconvulsive effects, 1005
analgesia
diazepam
drug interaction
meperidine
normeperidine
Profadol, 487
operant behavior
pigeon
Progesterone, 875
amphetamine
apomorphine
estrogen
sexual behavior, female rat
stereotyped behavior
Propyl-β-carboline-3-carboxylate, 245
benzodiazepine receptors
diazepam
ligand binding
multicomponent receptor
photoaffinity labeling
sparing from inactivation
Protein
amphetamine, 303
anorexia, 303
caloric intake, 303
caloric intake patterns, 949
carbohydrate, 303, 949
dietary self-selection, 303, 949
eating, 303, 949
β-endorphin, 949
fat, 303, 949
fenfluramine, 303
morphine, 949
Protein synthesis, 185
abrin
DNA synthesis
human peripheral lymphocytes
virus transformed lymphocytes

Proteo-N,N-dimethyltryptamine, 811
behavior disruption
kinetic isotope effect
tetradeutero-N,N-dimethyltryptamine
Psychomotor stimulants, 417
catecholamines
isolation
play
social behavior
Punishment-conflict, 279
chlordiazepoxide
extinction
6-hydroxydopamine, neonatal
norepinephrine depletion
Pyridoxine, 361
hypothermia
metabolism
vitamin B_6

Quinine, 293
dopamine theory of reward
finickiness
hyperphagia
lesions, hypothalamic
licking behavior
pimozide
sweet reward

Rat pups, 481
milk-induced behavior
mouthing
serotonergic agents
Rate-dependency, 745
caffeine
schedule-controlled responding
time course
Receptor binding, 841
behavioral efficacy
isolation rearing
opiates
Recovery of function, 769
emotionality
haloperidol
hyperirritability
lesions, septal
septal rage
Regional brain monoamines, 145
alcohol preference, rats
dopamine
5-hydroxyindoleacetic acid
norepinephrine
serotonin
Reinforcement
anesthetics, local, 491
behavioral arousal, 667
concurrent schedules, 393
dopamine, 667
drinking, 393
drug discrimination, 491
ethanol, 393
extinction, 667
multiple schedule, 667
operant responding, 667
pimozide, 667
relative responding, 393
self-administration, 491
species differences, 491
successive discrimination, 667
Relative responding, 393
concurrent schedules
drinking
ethanol
reinforcement

REM sleep
clorgyline, 429
cobalt epilepsy, 573
drug administration, "lifetime", 429
drug administration, subacute, 429
marijuana cannabinoids, 573
monoamine oxidase, 429
seizures, epileptic, 573
sleep stages, 429
tetrahydrocannabinols, 573
Renal electrolyte excretion, 909
appetite
drinking
eating
naltrexone
renal water excretion
water exchange
Renal water excretion, 909
appetite
drinking
eating
naltrexone
renal electrolyte excretion
water exchange
Repeated sampling, 693
blood ethanol
breath ethanol analyzer
Reserpine rigidity, 731
alpha adrenergic antagonists
alpha-2 receptors
autonomic responses
extrapyramidal effects
motor responses
Respiration, 599
endorphins
naloxone
stress
Response chains, 159
drug interaction
multiple schedule
operant behavior
patas monkeys
pentobarbital
phencyclidine
supra-additive effects
Response duration, 815
albinism
pentobarbital
sex differences
Response latency, 805
avoidance training
cholinergic system
developmental psychopharmacology
scopolamine
Reversal learning, 541
avoidance
neuroleptics
spatial preference
striatectomy
Y-maze performance
Reward
amphetamine, 433
dorsal tegmentum, 433
drug self-administration, 181
ethanol, 181
naloxone, 433
prefrontal cortex, 433
self-stimulation, 433
Rhesus monkeys
abuse potential, 851
atropine methylnitrate, 423
atropine sulfate, 423
benactyzine, 605
concurrent schedules, 113
drinking, 113

drug concentration, 113
drug self-administration, oral, 113
eating, 579
fixed ratio schedules, 113
food deprivation, 579
d,l-glaucine·1.5 phosphate, 851
level pressing, 423
motor control, 423
operant behavior, 605
pentobarbital, 579
pentobarbital reinforcement, 113
primate equilibrium platform, 605
satiety, 579
self-administration, 851
self-administration, oral, 579
water intake, 113
Righting reflex, 467
active avoidance
anxiety
anxiolytics
barbital
barbiturates
brain drug levels
drug administration, chronic
tolerance
Ro 5-3663, 689
anxiety
chlordiazepoxide
convulsant benzodiazepine
GABA
Rotation, 737
barbiturates
GABA
phenobarbital
substantia nigra
Rotational behavior, 437
dopamine receptors
stereotyped behavior
Rotometer, 353
automatic recording
circling behavior
Route of delivery
amine-aldehyde metabolites, 995
drug interaction, 995
ethanol self-selection, 995
macaque monkey, female, 995
opioid peptides, 983
opioids, 983
tetrahydropapaveroline, ICV infusion, 995
thermoregulatory behavior, 983
RX 336-M, 929
arousal
grooming
homeostasis
morphine withdrawal syndrome
wet-dog shakes

Salsolinol, 827
alcohol
amine-aldehyde condensation product
drinking
naloxone
opiate receptors
tetrahydropapaveroline
Satiety
appetite, 701
bombesin, 701
bromergocryptine, 701
cholecystokinin octapeptide, 701
dopaminergic system, 701
dynorphin, 701
eating, 579, 701, 897
food deprivation, 579
opiates, 701
pentobarbital, 579
rhesus monkeys, 579
self-administration, oral, 579
somatostatin, 897
thyrotropin-releasing hormone, 701
vagus nerve, 897
Schedule-controlled responding, 745
caffeine
rate-dependency
time course
Schedule-induced esacpe, 683
fixed interval
morphine
pigeons
Schedule-induced polydipsia, 155
chronic ethanol intake
drinking
overdrinking
Scopolamine
anticholinergic drugs, 919
arecoline, 677
avoidance training, 805
central cholinergic mechanisms, 677
cholinergic system, 805
developmental psychopharmacology, 805
ferret, 677
memory, spatial, 919
memory, working, 919
nicotine, 677
oxotremorine, 677
predatory behavior, 677
response latency, 805
Sedative-hypnotics, 925
methaqualone
pituitary-adrenal system
plasma corticosterone
Seizures
afterdischarge thresholds, 1009
amphetamine, 631
amygdala, 1009
brain weight, 631
cocaine, 631
kindling, 1009
kindling, amygdaloid, 751
lead acetate, 631
mouse genotype, 631
opiates, 751
phencyclidine, 1009
Seizures, epileptic, 573
cobalt epilepsy
marijuana cannaboinoids
REM sleep
tetrahydrocannabinols
Selective breeding
alcohol, 707
alcohol preference, 125, 501
drinking, 501, 707
drug interaction, 473, 707
ethanol concentration and distribution, 125
ethanol sensitivity, 125, 473
free-choice alcohol consumption, 501
hypothermia, 473
Maudsley rats, 707
morphine, 473, 707
opiates, 473
pharmacogenetics, 473
physical dependence, 501
strain differences, 707
withdrawal, 501
Self-administration
abuse potential, 851
anesthetics, local, 491
drug discrmination, 491
d,l-glaucine·1.5 phosphate, 851

reinforcement, 491
rhesus monkeys, 851
species differences, 491
Self-administration, oral, 579
eating
food deprivation
pentobarbital
rhesus monkeys
satiety
Self-injury, 957
p-chloroamphetamine
p-chlorophenylalanine
diazepam
dopaminergic mechanisms
haloperidol
pemoline
pimozide
Self-stimulation
amphetamine, 433
d-amphetamine, 791
analgesia, 81
apomorphine, 859
bupropion, 791
chlordiazepoxide, 795
CL218,872, 795
clonidine, 785
clozapine, 785
conflict, 795
diazepam, 17, 795
dopamine, 859
dorsal tegmentum, 433
extinction, 859
haloperidol, 785
hippocampus, 17
hypothalamus, 17
methocarbamol, 785
metoclopramide, 785
naloxone, 433
opiates, 81
pentobarbital, 795
pipradol, 791
prazosin, 785
prefrontal cortex, 433
reward, 433
shuttlebox, 785, 791, 795
stereotypy, 859
Sensorimotor dysfunction, 455
asymmetry
catecholamines
lesions, electrolytic
lesions, nigrostriatal
lesions, 6-OHDA
lesions, substantia nigra
sensory extinction
Sensory extinction, 455
asymmetry
catecholamines
lesions, electrolytic
lesions, nigrostriatal
lesions, 6-OHDA
lesions, substantia nigra
sensorimotor dysfunction
Sensory-motor conditioning hypothesis, 67
dopamine receptor blockade
extinction
pimozide
Septal rage, 769
emotionality
haloperidol
hyperirritability
lesions, septal
recovery of function
Serotonergic agents, 481
milk-induced behavior
mouthing
rat pups
Serotonergic development, 203
locomotor activity
methysergide
neonates, mice
thyroxine
Serotonin (5-HT)
β-adrenoceptor antagonists, 741
alcohol, 321
alcohol preference, rats, 145
antinociception, 47
aspartate, 509
biogenic amine metabolites, 641
biogenic monoamine turnover, 641
calcium-sodium ratio, 321
cats, 51
catecholamines, 441
p-chlorophenylalanine, 777
convulsions, tonic, 441
development, 441
dopamine, 47, 145, 321, 407, 509, 641, 741
electroshock, 441
ethanol, 321
GABA, 509
glutamate, 509
gnawing, 407
hallucinogens, 51
HPLC, 641
5-hydroxyindoleacetic acid, 145
5-hydroxytryptophan, 777
hyponeophagia, 741
hypothermia, 321
intrathecal injections, 407
lordosis, 777
LSD, 51
5-MeODMT, 741
monoamines, 441
morphine self-administration, 509
neophobia, 741
neurotransmitter turnover rates, 509
noradrenaline, 777
norepinephrine, 47, 145, 321, 509, 641
one compartment electrochemical detector cell, 641
opiate reinforcement systems, 509
poikilothermia, 321
regional brain monoamines, 145
sexual behavior, female rat, 777
stress, 47
tail-flick, 47
tail-pinch, 407
temperature set-point, 321
thermoregulation, 321
l-tryptophan, 51
visual evoked responses, 51
Serotonin metabolism, 229
dopamine metabolism
homovanillic acid
MIF-1
norepinephrine metabolism
striatum
tyrosine hydroxylase
Serotonin release, 881
active avoidance
central monoamines
p-chloroamphetamine
Sex differences
albinism, 815
amphetamine, 565
attention, 377
castration, 565
catecholamine interactions, 377
dopamine, 377
gerbils, 377
habituation, 377
lizards, 1017

locomotor activity, 377
MIF-I, 1017
norepinephrine, 377
ovariectomy, 565
pentobarbital, 815
response duration, 815
stereotyped behavior, 565
tonic immobility, 1017
Sexual behavior, female rat
amphetamine, 875
androgen receptors, 837
5α-androstane-β,17β-diol, 837
apomorphine, 875
p-chlorophenylalanine, 777
5α-dihydrotestosterone, 211
estrogen, 211, 875
estrogen receptors, 837
5-hydroxytryptophan, 777
hypothalamic cytosol, 837
lesions, electrolytic, 211
lesions, 6-OHDA, 211
lesions, septal nuclei, 211
lordosis, 211, 777, 837
mesolimbic dopamine pathway, 211
mounting behavior, 837
noradrenaline, 777
ovariectomy, 211, 837
progesterone, 875
serotonin, 777
stereotyped behavior. 875
Shock history, 329
anxiety
conditioned emotional response
GABA
neurotransmitter metabolism
stress
Shuttlebox, 943
acquisition, 943
d-amphetamine, 791
avoidance, 943
bupropion, 791
chlordiazepoxide, 795
CL218,872, 795
clonidine, 785
clozapine, 785
conflict, 795
diazepam, 795
extinction, 943
haloperidol, 785
intertrial response, 943
methocarbamol, 785
metoclopramide, 785
pentobarbital, 795
prazosin, 785
self-stimulation, 785, 791, 795
TRH, 943
Sleep stages, 429
clorgyline
drug administration, "lifetime"
drug administration, subacute
monoamine oxidase
REM sleep
Social behavior
aggression, 569
catecholamines, 417
isolation, 417
locomotor activity, 569
methadone, 569
play, 417
psychomotor stimulants, 417
Social bonding, 653
grooming
opiate antagonists
plasma hormone levels
talapoin monkeys
Sodium retention, 697
aldosterone
angiotensin II
food deprivation
hypovolemia
plasma osmolality
Somatostatin, 897
eating
satiety
vagus nerve
Sparing from inactivation, 245
benzodiazepine receptors
diazepam
ligand binding
multicomponent receptor
photoaffinity labeling
propyl-β-carboline-3-carboxylate
Spatial behavior, 915
cerebral asymmetry
copper
hippocampus
lateralization
zinc
Spatial preference, 541
avoidance
neuroleptics
reversal learning
striatectomy
Y-maze performance
Species differences, 491
anesthetics, local
drug discrmination
reinforcement
self-administration
Spinal cord monoamines, 615
ontogeny
post-decapitation reflex
^{3}H-spiroperidol binding, 119
dopamine receptors
hypersensitivity
locomotor activity
mesolimbic area
neuroleptics
opiates
stereotypy
striatum
Spontaneous activity
chronic opiate administration, 263
development, 761
haloperidol, 761
hyperactivity, 263
hypoactivity, 263
in utero studies, rats, 263
morphine tolerance, 263
operant conditioning, 761
postnatal treatment, 761
withdrawal, 263
Startle reflex, 869
analgesia
morphine
nociceptive stimuli
Stereotyped behavior
amphetamine, 565, 875
apomorphine, 875
castration, 565
dopamine receptors, 437
estrogen, 875
ovariectomy, 565
progesterone, 875
rotational behavior, 437
sex differences, 565
sexual behavior, female rat, 875
Stereotypy
apomorphine, 235, 859
dopamine, 859

dopamine receptors, 119, 285
dopaminergic agonists, 235
estrogen, 285
estrous cycle, female rat, 285
extinction, 859
hypersensitivity, 119
locomotor activity, 119
mesolimbic area, 119
neuroleptics, 119
opiates, 119
self-stimulation, 859
^{3}H-spiroperidol binding, 119
striatal dopamine receptors, 235
striatum, 119, 285
Stimulants, 449
antidepressants
anxiolytics
depressants
depression
electroconvulsive shock
learned helplessness
neuroleptics
Strain differences, 707
alcohol
drinking
drug interaction
Maudsley rats
morphine
selective breeding
Stress
adrenalectomy, 403
alcohol dependence, 253
analgesia, 403
antinociception, 47
antidepressants, 969, 973
anxiety, 329
brain region differences, 637
buprion, 973
conditioned emotional response, 329
conditioned taste aversion, 253
corticosterone, 585
defecation, 969
depression, animal model, 969, 973
dexamethasone, 403
diphenhydramine, 591
dopamine, 47
endorphins, 599
fetal ethanol, 585
footshock, 637
GABA, 329
histamine levels, 591
histidine decarboxylase, 591
hypothalamic-pituitary-adrenal system, 585
imipramine, 969
iprindole, 973
MHPG-SO_4, 637
mianserine, 973
naloxone, 599
neurotransmitter metabolism, 329
noradrenaline turnover, 637
norepinephrine, 47
open field, 969
pain, 403
plasma corticosterone, 591, 973
prenatal ethanol, 585
respiration, 599
serotonin, 47
shock history, 329
tail-flick, 47
withdrawal, 253
Stress, immobilization, 315
brain, regional differences
MHPG-SO_4
noradrenaline turnover
plasma corticosterone
time-related differences
Striatal dopamine receptors, 235
apomorphine
dopaminergic agonists
stereotypy
Striatectomy, 541
avoidance
neuroleptics
reversal learning
spatial preference
Y-maze performance
Striatum
dopamine metabolism, 229
dopamine receptors, 119, 285
estrogen, 285
estrous cycle, female rat, 285
homovanillic acid, 229
hypersensitivity, 119
locomotor activity, 119
mesolimbic area, 119
MIF-1, 229
neuroleptics, 119
norepinephrine metabolism, 229
opiates, 119
serotonin metabolism, 229
^{3}H-spiroperidol binding, 119
stereotypy, 119, 285
tyrosine hydroxylase, 229
Structure-activity, 819
behavioral effects
neurohypophyseal hormone analogs
oxytocin
vasopressin
Substantia nigra, 737
barbiturates
GABA
phenobarbital
rotation
Successive discrimination, 667
behavioral arousal
dopamine
extinction
multiple schedule
operant responding
pimozide
reinforcement
Supra-additive effects, 159
drug interaction
multiple schedule
operant behavior
patas monkeys
pentobarbital
phencyclidine
response chains
Sweet reward, 293
dopamine theory of reward
finickiness
hyperphagia
lesions, hypothalamic
licking behavior
pimozide
quinine
Swimming, 207
cardiac mass
ethanol
mitochondrial function

Tail-flick, 47
antinociception
dopamine
norepinephrine
serotonin
stress

Tail-pinch, 407
dopamine
gnawing
intrathecal injections
serotonin
Talapoin monkeys, 653
grooming
opiate antagonists
plasma hormone levels
social bonding
Temazepam, 529
antileptazol
anxiolytics
benzodiazepine receptors
camazepam
clobazam
diazepam binding
oxazepam
Temperature set-point, 321
alcohol
calcium-sodium ratio
dopamine
ethanol
hypothermia
norepinephrine
poikilothermia
serotonin (5-HT)
thermoregulation
Testosterone metabolism, 933
body weight
eating
prepubertal male rat
Tetradeutero-N,N-dimethyltryptamine, 811
behavior disruption
kinetic isotope effect
proteo-N,N-dimethyltryptamine
Tetrahydrocannabinols, 573
cobalt epilepsy
marijuana cannabinoids
REM sleep
seizures, epileptic
Tetrahydropapveroline, 827
alcohol
amine-aldehyde condensation product
drinking
naloxone
opiate receptors
slasolinol
Tetrahydropapaveroline, ICV infusion, 995
amine-aldehyde metabolites
drug interaction
ethanol self-selection
macaque monkey, female
route of delivery
Thermogenesis, 627
brown adipose tissue
isoproterenol
obesity
Zucker rats
Thermoregulation
alcohol, 321
body temperature, 23
calcium-sodium ratio, 321
capsaicin, 23
dopamine, 321
ethanol, 321
FK 33-824, 989
hyperthermia, 989
hypothalamic temperature, 23
hypothermia, 321
naloxone, 989
norepinephrine, 321
opioid peptides, 989
opioid receptors, 989
poikilothermia, 321
serotonin (5-HT), 321
temperature set-point, 321
Thermoregulatory behavior, 983
opioid peptides
opioids
route of delivery
Thyrotropin-releasing hormone (TRH)
acquisition, 943
appetite, 225, 701
avoidance, 943
bicuculline, 225
bombesin, 225, 701
bromergocryptine, 701
calcitonin, 225
cholecystokinin octapeptide, 225, 701
dopaminergic system, 701
dynorphin, 701
eating, 225, 701
extinction, 943
histidyl-proline diketopiperazine, 225
intertrial response, 943
naloxone, 225
norepinephrine-induced feeding, 225
opiates, 701
satiety, 701
shuttlebox, 943
Thyroxine, 203
locomotor activity
methysergide
neonates, mice
serotonergic development
Time course, 745
caffeine
rate-dependency
schedule-controlled responding
Time-related differences, 315
brain, regional differences
MHPG-SO_4
noradrenaline turnover
plasma corticosterone
stress, immobilization
Tolerance
active avoidance, 467
ambient temperature, 903
anticonvulsant drugs, 843
anxiety, 467
anxiolytics, 467
barbital, 467
barbiturates, 467
blood glucose levels, 903
body temperature, 903
brain drug levels, 467
cocaine, 661, 713
conditional discrmination, 713
conditional drug states, 661
cross-potentiation, 661
drug administration, chronic, 467
ethanol, 903
fixed-ratio schedule, 843
hypothermia, 903
matching-to-sample, 713
memory, 713
Pavlovian conditioning, 661
pentobarbital, 661
phenytoin, 843
pigeons, 713, 843
righting reflex, 467
Tonic immobility, 1017
lizards
MIF-I
sex differences
Tranquilizers, 397
bicuculline
dorsal periaqueductal gray
electrical stimulation

flight behavior
GABA mediation
picrotoxin
Triazolopyridazine CL218,872, 373
benzodiazepine receptors
brain, ovine
^{3}H-diazepam binding
Tripelennamine, 979
antihistamines
anxiolytics
benzodiazepine
corticosterone
defecation
depression, animal model
haloperidol
neuroleptics
open field
oxazepam
l-Tryptophan, 51
cats
hallucinogens
LSD
serotonin (5-HT)
visual evoked responses
Tyrosine hydroxylase, 229
dopamine metabolism
homovanillic acid
MIF-1
norepinephrine metabolism
serotonin metabolism
striatum

Vagus nerve, 897
eating
sateity
somatostatin
Vasopressin
amnesia, 463
anisomycin, 463
behavioral effects, 819
brain, mouse, 139
cyclic AMP, 139
memory retrieval, 463
neurohypophyseal hormone analogs, 819
oxytocin, 819
passive avoidance, 463
structure-activity
Ventral mesencephalic tegmental area (nucleus A10), 547
aggression
dopaminergic system
lesions, 6-OHDA
mesocorticolimbic system
muricide
Ventromedial hypothalamus, 93
eating
estrogen and food intake
nitromifene citrate (CI-628)
Virus transformed lymphocytes, 185
abrin
DNA synthesis
human peripheral lymphocytes
protein synthesis
Visual evoked responses, 51
cats
hallucinogens
LSD
serotonin (5-HT)
l-tryptophan
Vitamin B_6, 361
hypothermia
metabolism
pyridoxine

Water exchange, 909
appetite
drinking
eating
naltrexone
renal electrolyte excretion
renal water excretion
Water intake, 113
concurrent schedules
drinking
drug concentration
drug self-administration, oral
fixed ratio schedules
pentobarbital reinforcement
rhesus monkeys
Wet-dog shakes, 929
arousal
grooming
homeostasis
morphine withdrawal syndrome
RX 336-M
Withdrawal
adrenal medulla, 719
alcohol dependence, 253
alcohol preference, 501
catecholamines, 719
chronic opiate administration, 263
conditioned taste aversion, 253
drinking, 501
ethanol, 719
free-choice alcohol consumption, 501
hyperactivity, 263
hypoactivity, 263
in utero studies, rats, 263
morphine tolerance, 263
physical dependence, 501, 719
selective breeding, 501
spontaneous activitiy, fetal rat, 263
stress, 253

Y-maze performance, 541
avoidance
neuroleptics
reversal learning
spatial preference
striatectomy

Zinc, 915
cerebral asymmetry
copper
hippocampus
lateralization
spatial behavior
Zucker rats, 627
brown adipose tissue
isoproterenol
obesity
thermogenesis

Pharmacology Biochemistry & Behavior, Vol. 16. Copyright © 1982 by Ankho International Inc. Printed in the U.S.A.

AUTHOR INDEX

ALLAN, A. M., 35
ALLEN, D. L., 757
ADAMS, M. A., 719
AIGNER, T., 851
ALEXANDER, G. J., 801
ALKANA, R. L., 341
ANDERSON, R. J., 731
ARAVICH, P. F., 101
ARBUTHNOTT, G. W., 197
ARDIES, C. M., 207
ARUSHANIAN, E. B., 541
ATALAY, J., 841

BAEZ, L. A., 533
BAKER, T. B., 253
BALDRIGHI, G., 969
BALSTER, R. L., 491
BARKER, S. A., 811
BARNES, C. D., 909
BARTNESS, T. J., 1001
BATURIN, V. A., 541
BAUER, R. H., 217
BAUM, M. J., 211
BEATON, J. M., 811
BEATTY, W. W., 417, 565, 919
BENINGER, R. J., 667
BENNETT, C. E., 185
BENNETT, C. T., 605
BERMAN, R. F., 751
BERMOND, B., 41
BERNARDINI, G. L., 989
BIALIK, R. J., 279
BIDZIŃSKI, A., 547
BIELKIEWICZ, B., 591
BLACKBURN, T. P., 7
BLASS, R. B., 235
BODNAR, R. J., 411
BOGGAN, W. O., 925
BOLAM, J. M., 815
BONNEY, R. C., 777
BLUM, K., 13
BRANCH, B. J., 585
BRANCH, M. N., 713
BRANDÃO, M. L., 397
BREE, M. P., 521
BRICK, J., 473, 693
BRIGGS, A. H., 13
BRITT, M. D., 841
BROADHURST, P. L., 741
BROWN, C., 155
BROWN, J. W., 73
BROWN, R. E., 745
BURRIGHT, R. G., 631
BURT, D. K., 533
BUTERBAUGH, G. G., 441
BUXTON, D. A., 741
BUXTON, M., 151

CACCIA, S., 529
CALCAGNETTI, D. J., 173
CAMPBELL, I. C., 429
CAMPBELL, K. A., 17
CAPPELL, H., 661
CAREY, R. J., 859
CARLSON, K. R., 119
CASHNER, F. M., 1017
CASTELLANO, C., 561
CAUDARELLA, M., 17
CAZA, P. A., 481
CHARLESON, S., 841
CHEAL, M. L., 377
CHEREK, D. R., 329
CLARK, W. G., 983, 989
CO, C., 509, 641
COHEN, R. M., 429
COLASANTI, B. K., 573
CONCANNON, J. T., 1
COTECCHIA, S., 529
COVENEY, J. R., 937
COWAN, A., 929
COX, B., 7
CRAIG, C. R., 573
CRAWFORD, D., 253
CRITCHER, E. C., 827
CROWNER, M. L., 533

DALLEMAGNE, G., 761
DE AGUIAR, J. C. , 397
DEARING, M. E., 713
DE-LA-CRUZ, F., 177
DELALLO, L., 13
DELATTE, S. W., 1017
DENOBLE, V. J., 113
DE RYCK, M., 285
DEWEY, W. L., 47
DE WIED, D., 387
DIB, B., 23
DIRINGER, M. N., 73
DODGE, A. M., 417, 565
DODGE, L. J., 417
DOERING, C. H., 837
DOLINSKY, Z., 631
DONOHOE, T. P., 93
DONOVICK, P. J., 631
DUCLAUX, R., 241
DUNCAN, P. M., 1009

EGGLETON, C., 751
ELLIOTT, M. L., 63
ELSHOWIHY, R. M., 599
ELSTON, S. F. A., 13
ERICKSON, C. K., 207
ERSKINE, M. S., 211
EVERARD, D. M., 777

FABRE-NYS, C., 653
FALK, J. L., 155
FANELLI, R. J., 631
FARRAR, R. P., 207
FARRAR, S. B., 455
FARRER, D. N., 605
FEIGENBAUM, J. J., 235
FEKETE, M., 387
FELDON, J., 689
FELT, B. T., 139
FIBIGER, H. C., 197
FOLTIN, R. W., 347
FORSTER, M. J., 203
FRANKLIN, K. B. J., 433
FRAZIER, J. M., 915
FREEMAN, F. G., 1009
FREEMAN, M. E., 329, 509
FREEMAN, P. R., 569
FUJITA, N., 437

GARATTINI, S., 529
GARDNER, E. L., 769
GERHARDT, S., 791, 795
GIESKE, T. H., 851
GILLIAM, P., 455
GILLIN, J. C., 429
GLADUE, B. A., 837
GLASSMAN, A. B., 185
GLENNON, R. A., 553, 557
GLUCKMAN, P. D., 373
GMEREK, D. E., 929
GODDING, P. R., 919
GOLDMAN, H., 139
GOLDSTEIN, F. J., 51
GRACE, M., 701
GRAEFF, F. G., 397
GRUNDMAN, M., 933

HADFIELD, M. G., 359
HALL, N., 785
HANFORD, P. V., 467
HARRIS, P. S., 467
HARTMANN, G., 403
HARTWELL, S. W., 915
HARVEY, K. L., 521
HAUPTMANN, M., 547
HEAPY, C. G., 7
HENDRICKS, C., 855
HERZ, A., 249
HICKS, R. A., 361
HINSON, R. E., 661
HIRATA, A., 437

HIRSCH, J. D., 245
HIRST, M., 719
HOAKI, Y., 637
HOLTZMAN, S. G., 263
HOROWITZ, G. P., 35, 473
HORWITZ, B. A., 627
HOWE, S. J., 725
HRUSKA, R. E., 285
HUNGERFORD, S. M., 533

IDA, Y., 315, 637
IIMORI, K., 637
INGS, R., 615
ISOM, G. E., 599
ISON, J. R., 869

JARVIS, M. F., 1009
JENSEN, M. A., 271
JERUSSI, T. P., 353
JOHANSON, C. E., 851
JUDGE, M. E., 463

KAMEYAMA, Y., 943
KANAREK, R. B., 303
KARPIAK, S. E., 611
KATZ, R. J., 965, 969, 973, 979
KELLAR, K. J., 647
KEVERNE, E. B., 653
KHAZAN, N., 167
KIRBY, M. L., 263
KLAWANS, H., 235
KLINER, D. J., 579
KNEIP, J., 225, 701
KOHNO, Y., 315, 637
KOKKA, N., 585
KONDZIELSKI, M. H., 407
KOSTOWSKI, W., 547
KRAFFT, K., 843
KRAMARCY, N. R., 73
KRUK, M. R., 41

LANE, J. D., 329, 509, 641
LANG, I. M., 909
LARSON, A. A., 407
LEANDER, J. D., 487, 1005
LEE, T. F., 7
LEIBOWITZ, S. F., 101
LE MAGNEN, J., 181
LEVINE, A. S., 225, 897
LEVINE, A. S., 701
LEWIS, M. E., 29
LI, T.-K., 125, 145, 501
LIEBERMAN, K. W., 801
LIEBMAN, J. M., 785, 791, 795
LINDAMOOD III, C., 573
LINDSETH, K. A., 361
LITTLE, R. G. II, 757
LIU, S. H., 585
LIU, W.-F., 811
LOBAUGH, N., 455
LOF, N. E., 605
LOGAN, N., 769
LONDON, E. D., 441
LUDMER, L. M., 285
LUMENG, L., 125, 145, 501
LUTHERER, L. O., 909

McBRIDE, W. J., 125, 145, 501
McCALEB, M. L., 995
McCARTHY, P. S., 725, 1013
McDEVITT, J. T., 737
MALCOLM, R. D., 341
MALSEED, R. T., 51
MANDEL, P., 57
MAREK, P., 403
MARKS-KAUFMAN, R., 949
MAROTTA, R. F., 769
MASUR, J., 903
MATTSSON, J. L., 605
MAZURKIEWICZ-KWILECKI, I. M., 591
MEELIS, W., 41
MEIERL, G., 677
MEISCH, R. A., 113, 579
MEISENBERG, G., 819
MELISKA, C. J., 745
MELLER, R. E., 653
MELLO, N. K., 521
MENDELSON, W. B., 429
MENNINI, T., 529
MENNITI, F. S., 211
MESSING, R. B., 621
METCALF, G., 725
MEYER, J. S., 925
MEYERSON, B. J., 875
MICHANEK, A., 875
MICHELS, K., 631
MILAM, K. M., 627
MILGRAM, N. W., 17
MINAMI, H., 311
MISRA, A. L., 847
MOERSCHBAECHER, J. M., 159, 647
MOON, B., 235
MOORE, K. E., 131
MORLEY, J. E., 225, 701, 897
MOS, J., 41
MOTT, D. E. W., 359
MUELLER, K., 957
MURPHY, D. L., 429
MURPHY, J. M., 145
MURRAY, S. S., 225
MYERS, R. D., 321, 827, 995
MYSLOBODSKY, M., 689

NAGASAKI, N., 315, 637
NAGAYAMA, H., 311
NAGY, Z. M., 203
NAKAGAWA, R., 315, 637
NICOTERA, N., 411
NIELSEN, J. A., 131
NISHIWAKI, K., 311
NUGENT, E. A., 359
NUNEZ, A. A., 933
NYHAN, W. L., 957

ÖGREN, S. O., 881
OKAMOTO, M., 801
OLIVEIRA SOUZA, M. L., 903
OLSON, G. A., 1017
OLSON, R. D., 1017
ORTHEN-GAMBILL, N., 303

PANKSEPP, J., 417
PANOCKA, I., 403
PAPPAS, B. A., 151, 279, 615
PARROTT, R. F., 777
PETERSEN, D. R., 757
PETTY, F., 449
PITMAN, K. T., 285
PLONSKY, M., 569
POHORECKY, L. A., 693
POLING, A., 843
PONDER, S. W., 989
PONTANI, R. B., 847
PORTOGHESE, P. S., 621
POULOS, C. X., 661
PRESHAW, R. L., 81
PRESTON, K. L., 423
PROWSE, J., 785, 791, 795
PUCILOWSKI, O., 547
PUGLISI-ALLEGRA, S., 57, 561
PURVIS, P. L., 719
PUSZTAY, W., 151, 279

QUARTERMAIN, D., 463

RASTOGI, R. B., 229
REID, L. D., 173
RICHTER, J. A., 467
RIVERSO, S., 769
ROBERTSON, A., 433
ROEHRS, T. A., 393
ROSECRANS, J. A., 553, 557
ROSSI, G. V., 51
ROWLAND, N., 87, 1001
RUSH, J. R., 919
RUSSEK, M., 177
RUWE, W. D., 321, 995

SACQUITNE, J. L., 449
SAITO, K., 437
SAMSON, H. H., 393
SANDS, M. P., 329
SANGER, D. J., 1013
SATINDER, K. P., 707
SATO, S. M., 915
SAUMET, J-L, 241
SBORDONE, R. J., 63
SCHALLERT, T., 455
SCHECHTER, M. D., 1
SCHENK, S., 841
SCHMIDT, W. J., 677
SCHNEIDER, D. R., 139
SCHULZ, E. M., 697
SCHUSTER, C. R., 347, 423, 851
SCHWARTZ, R. D., 647
SCLAFANI, A., 101, 293
SEEGER, T. F., 119
SHEARMAN, G. T., 249
SHEPHARD, R. A., 741
SHERMAN, A. D., 449
SHOREY, R. A. L., 207
SIBEL, M., 973, 979
SILBERGELD, E. K., 285
SIMLER, S., 57
SIMMONS, W. H., 819
SINDEN, J. D., 181
SINGHAL, R. L., 229
SIVIY, S. M., 173
SLIFER, B. E., 683
SMITH, C. C., 29
SMITH, G. J., 805
SMITH, J. E., 329, 509, 641
SNOW, A. E., 47
SPARBER, S. B., 621, 937
SPEAR, L. P., 481, 805
SPEAR, N. E., 805
SPIRDUSO, W. W., 455
SPYRAKI, C., 197
STEINFELS, G. F., 167
STERN, J. S., 627
STEVENS, R., 93
STOKES, P. E., 801
STONE, W. S., 751
STRAHLENDORF, H. K., 909
STRAHLENDORF, J. C. R., 51, 909
STRIPLING, J. S., 855
STUTZ, R. M., 81
SVIKIS, D. S., 113
SZOSTAK, C., 67

TAKAGI, A., 311
TAKAHASHI, R., 311
TAKEDA, S., 315
TAKEMORI, A. E., 621
TALLMAN, J. F., 29
TAMAKI, Y., 943
TANAKA, M., 315, 637
TANG, M., 155
TAYLOR, A. N., 585
TAYLOR, K. M., 373
THEOTOKATOS, J. E., 757
THOMPSON, D. M., 159, 647
THOMPSON, T. I., 271
THURMOND, J. B., 73
TOBET, S. A., 211
TOMBAUGH, J. W., 67
TOMBAUGH, T. N., 67
TRIANA, E., 801
TRAYLOR, K. L., 565
TSUDA, A., 637
TUCKER, S. M., 47

UPCHURCH, M., 455

VADLAMANI, N. L., 847
VALDES, J. J., 915
VAN DER POEL, A. M., 41
VAUGHN, D., 455
VICKERS, G., 151
VILLIGER, J. W., 373
VOCCI, F. J., 441
VON ALMEN, T. K., 1017
VOORNEVELD, P., 67

WAGNER, B. H., 731
WALLER, M. B., 125, 501
WALLER, S. B., 441
WARREN, P. H., 869
WEBB, S. A., 521
WEISS, B., 761
WESTENBERG, I. S., 815
WHITE, K., 417
WILCOX, R. E., 455
WILSON, C. A., 777
WITTEN, M., 185
WISE, J., 777
WOOLVERTON, W. L., 491
WRIGHT, J. W., 697
WYATT, R. J., 429

YANAI, J., 235
YOCHMOWITZ, M. G., 605
YOSHIDA, H., 437
YOSHIMOTO, S., 311
YOUNG, G. A., 167
YOUNG, R., 553, 557
YUNGER, L. M., 737

XENAKIS, S., 293

ZENICK, H., 81

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 16 NUMBER 1 JANUARY 1982

CONTENTS

Haloperidol-induced hyperactivity in neonatal rats: Effect of lithium and stimulants. SCHECHTER, M. D. and J. T. CONCANNON 1

Possible mechanism of 5-methoxy-N,N-dimethyltryptamine-induced turning behaviour in DRN lesioned rats. BLACKBURN, T. P., B. COX, C. G. HEAPY and T. F. LEE 7

Ethanol intoxication as a function of genotype dependent responses in three inbred mice strains. ELSTON, S. F. A., K. BLUM, L. DELALLO and A. H. BRIGGS 13

Differential effects of diazepam (Valium) on brain stimulation reward sites. CAUDARELLA, M., K. A. CAMPBELL and N. W. MILGRAM 17

Effects of intracerebroventricular capsaicin on thermoregulatory behavior in the rat. DIB, B. 23

Effect of benzodiazepines on cyclic GMP formation in rat cerebellar slices. SMITH, C. C., M. E. LEWIS and J. F. TALLMAN 29

Morphine withdrawal in mice selectively bred for differential sensitivity to ethanol. HOROWITZ, G. P. and A. M. ALLAN 35

Aggression induced by stimulation of the hypothalamus: Effects of androgens. BERMOND, B., J. MOS, W. MEELIS, A. M. VAN DER POEL and M. R. KRUK 41

The role of neurotransmitters in stress-induced antinociception (SIA). SNOW, A. E., S. M. TUCKER and W. L. DEWEY 47

Differential effects of LSD, serotonin and *l*-tryptophan on visually evoked responses. STRAHLENDORF, J. C. R., F. J. GOLDSTEIN, G. V. ROSSI and R. T. MALSEED 51

γ-Aminobutyric acid in brain areas of isolated aggressive or non-aggressive inbred strains of mice. SIMLER, S., S. PUGLISI-ALLEGRA and P. MANDEL 57

Drug-induced ataxia in opponents elicits "pathological" fighting in undrugged rats exposed to footshock. ELLIOTT, M. L. and R. J. SBORDONE 63

Failure to obtain functional equivalence between dopamine receptor blockade and extinction: Evidence supporting a sensory-motor conditioning hypothesis. TOMBAUGH, T. N., C. SZOSTAK, P. VOORNEVELD and J. W. TOMBAUGH 67

Effect of fusaric acid on aggression, motor activity, and brain monoamines in mice. DIRINGER, M. N., N. R. KRAMARCY, J. W. BROWN and J. B. THURMOND 73

Effects of parenteral morphine and oral methadone on self-stimulation in the rat. PRESHAW, R. L., H. ZENICK and R. M. STUTZ 81

Comparison of the suppression by naloxone of water intake induced in rats by hyperosmolarity, hypovolemia, and angiotensin. ROWLAND, N. 87

Modulation of food intake by hypothalamic implants of estradiol benzoate, estrone, estriol and CI-628 in female rats. DONOHOE, T. P. and R. STEVENS 93

Effects of hypothalamic knife cuts on feeding induced by paraventricular norepineprine injections. ARAVICH, P. F., A. SCLAFANI and S. F. LEIBOWITZ 101

Orally delivered pentobarbital as a reinforcer for rhesus monkeys with concurrent access to water: Effects of concentration, fixed-ratio size, and liquid positions. DENOBLE, V. J., D. S. SVIKIS and R. A. MEISCH 113

Interaction of opiates with dopamine receptors: Receptors binding and behavioral assays. CARLSON, K. R. and T. F. SEEGER 119

Different sensitivies to ethanol in alcohol-preferring and -nonpreferring rats. LUMENG, L., M. B. WALLER, W. J. MCBRIDE and T. K. LI 125

Measurement of metabolites of dopamine and 5-hydroxytryptamine in cerebroventricular perfusates of unanesthetized, freely-moving rats: Selective effects of drugs. NIELSEN, J. A. and K. E. MOORE 131

Desglycyl-8-arginine vasopressin affects regional mouse brain cyclic AMP content. SCHNEIDER, D. R., B. T. FELT and H. GOLDMAN 139

Regional brain levels of monoamines in alcohol-preferring and -nonpreferring lines of rats. MURPHY, J. M., W. J. MCBRIDE, L. LUMENG and T.-K. LI 145

Infant rat hyperactivity elicited by home cage bedding is unaffected by neonatal telencephalic dopamine or norepinephrine depletion. PAPPAS, B. A., G. VICKERS, M. BUXTON and W. PUSZTAY 151

Complete reversal of chronic ethanol polydipsia by schedule withdrawal. TANG, M., C. BROWN and J. L. FALK 155

Phencyclidine in combination with pentobarbital: Supra-additive effects on complex operant behavior in patas monkeys. THOMPSON, D. M. and J. M. MOERSCHBAECHER 159

Self-administration of nalbuphine, butorphanol and pentazocine by morphine post-addict rats. STEINFELS, G. F., G. A. YOUNG and N. KHAZAN 167

BRIEF COMMUNICATIONS

A temporal analysis of naloxone's suppressant effect on drinking. SIVIY, S. M., D. J. CALCAGNETTI and L. D. REID 173

Dissociation between behavioral and electrocortical manifestations of electroshock convulsions during the action of an anticonvulsive drug. DE-LA-CRUZ, F. and M. RUSSEK 177

Parameters of low-dose ethanol intravenous self-administration in the rat. SINDEN, J. D. and J. LE MAGNEN 181

DNA and protein synthesis in normal and transformed lymphocytes exposed to brain. BENNETT, C. E., A. B. GLASSMAN and M. WITTEN 185

ANNOUNCEMENTS 191

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 16 NUMBER 2 FEBRUARY 1982

CONTENTS

The effect of DSP-4 on some positively reinforced operant behaviors in the rat. SPYRAKI, C., G. W. ARBUTHNOTT and H. C. FIBIGER 197

Development of serotonin-mediated behavioral inhibition in the hyperthyroid mouse. NAGY, Z. M. and M. J. FORSTER 203

The interaction of ethanol and swimming upon cardiac mass and mitochondrial function. FARRAR, R. P., C. M. ARDIES, R. L. SHOREY and C. K. ERICKSON 207

Dihydrotestosterone-induced inhibition of lordosis in estrogen-primed ovariectomized rats following 6-hydroxydopamine or electrolytic septal lesions. MENNITI, F. S., M. S. ERSKINE, S. A. TOBET and M. J. BAUM 211

Ontogenetic differences in response to d-amphetamine: Two-way avoidance, intertrial responses, and locomotor activity. BAUER, R. H. 217

Peptidergic regulation of norepinephrine induced feeding. MORLEY, J. E., A. S. LEVINE, S. S. MURRAY and J. KNEIP 225

MIF-1: Effects on norepinephrine, dopamine and serotonin metabolism in certain discrete brain regions. SINGHAL, R. L. and R. B. RASTOGI 229

The effect of drugs altering striatal dopamine levels on apomorphine induced stereotypy. FEIGENBAUM, J. J., J. YANAI, R. B. BLASS, B. MOON and H. KLAWANS 235

Analgesia induced by neonatal capsaicin treatment in rats. SAUMET, J.-L. and R. DUCLAUX 241

Photolabeling of benzodiazepine receptors spares [^{3}H]propyl β-carboline binding. HIRSCH, J. D. . 245

D-Ala^2,D-Leu^5-enkephalin generalizes to a discriminative stimulus produced by fentanyl but not ethylketocyclazocine. SHEARMAN, G. T. and A. HERZ 249

Alcohol dependence and taste-mediated learning in the rat. CRAWFORD, D. and T. B. BAKER 253

Effects of chronic opiate administration on spontaneous activity of fetal rats. KIRBY, M. L. and S. G. HOLTZMAN 263

Interaction of methadone and pentobarbital on chained fixed-interval performance in pigeons. JENSEN, M. A. and T. THOMPSON 271

Chlordiazepoxide-induced released responding in extinction and punishment-conflict procedures is not altered by neonatal forebrain norepinephrine depletion. BIALIK, R. J., B. A. PAPPAS and W. PUSZTAY 279

Effects of estrogen on striatal dopamine receptor function in male and female rats. HRUSKA, R. E., L. M. LUDMER, K. T. PITMAN, M. DE RYCK and E. K. SILBERGELD 285

The dopaminergic mediation of a sweet reward in normal and VMH hyperphagic rats. XENAKIS, S. and A. SCLAFANI 293

Differential effects of amphetamine and fenfluramine on dietary self-selection in rats. ORTHEN-GAMBILL, N. and R. B. KANAREK 303

Circadian rhythm of brain susceptibility to haloperidol during chronic administration. NAGAYAMA, H., A. TAKAGI, S. YOSHIMOTO, H. MINAMI, K. NISHIWAKI and R. TAKAHASHI 311

Time-related differences in noradrenaline turnover in rat brain regions by stress. TANAKA, M., Y. KOHNO, R. NAKAGAWA, Y. IDA, S. TAKEDA and N. NAGASAKI 315

Is alcohol induced poikilothermia mediated by 5-HT and catecholamine receptors or by ionic set-point mechanism in the brain? MYERS, R. D. and W. D. RUWE 321

Amino acid neurotransmitter utilization in discrete rat brain regions is correlated with conditioned emotional response. LANE, J. D., M. P. SANDS, M. E. FREEMAN, D. R. CHEREK and J. E. SMITH 329

Hyperbaric ethanol antagonism: Role of temperature, blood and brain ethanol concentration. MALCOLM, R. D. and R. L. ALKANA 341

The effects of cocaine in a gustatory avoidance paradigm: A procedural analysis. FOLTIN, R. W. and C. R. SCHUSTER 347

BRIEF COMMUNICATIONS

A simple, inexpensive rotometer for automatically recording the dynamics of circling behavior. JERUSSI, T. P. 353

Cocaine increases isolation-induced fighting in mice. HADFIELD, M. G., E. A. NUGENT and D. E. W. MOTT 359

Pyridoxine reduces core body temperature in rats. LINDSETH, K. A. and R. A. HICKS 361

ANNOUNCEMENTS 365

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 16 NUMBER 3 MARCH 1982

CONTENTS

Characteristics of Type 1 and Type 2 benzodiazepine receptors in the ovine brain. VILLIGER, J. W., K. M. TAYLOR and P. D. GLUCKMAN 373

Attention and habituation: Catecholamine interactions and sex differences. CHEAL, M. L. 377

Potency and duration of action of the ACTH 4–9 analog (ORG 2766) as compared to ACTH 4–10 and [D-Phe^7] ACTH 4–10 on active and passive avoidance behavior of rats. FEKETE, M. and D. DE WIED 387

Relative responding on concurrent schedules: Indexing ethanol's reinforcing efficacy. ROEHRS, T. A. and H. H. SAMSON 393

GABA mediation of the anti-aversive action of minor tranquilizers. BRANDÃO, M. L., J. C. DE AGUIAR and F. G. GRAEFF 397

Enhancement of stress-induced analgesia in adrenalectomized mice: Its reversal by dexamethasone. MAREK, P., I. PANOCKA and G. HARTMANN 403

Serotonin-induced gnawing in rats: Comparison with tail pinch-induced gnawing. LARSON, A. A. and M. H. KONDZIELSKI 407

Neuroleptic and analgesic interactions upon pain and activity measures. BODNAR, R. J. and N. NICOTERA 411

Psychomotor stimulants, social deprivation and play in juvenile rats. BEATTY, W. W., A. M. DODGE, L. J. DODGE, K. WHITE and J. PANKSEPP 417

A comparison of the central and peripheral effects of atropine on force lever performance. PRESTON, K. L. and C. R. SCHUSTER 423

Lifetime monoamine oxidase inhibition and sleep. MENDELSON, W. B., R. M. COHEN, I. C. CAMPBELL, D. L. MURPHY, J. C. GILLIN and R. J. WYATT 429

Effects and interactions of naloxone and amphetamine on self-stimulation of the prefrontal cortex and dorsal tegmentum. FRANKLIN, K. B. J. and A. ROBERTSON 433

Multiple postsynaptic dopamine receptors and behavioral manifestation. FUJITA, N., A. HIRATA, K. SAITO and H. YOSHIDA 437

Age-dependent reduction in maximum electroshock convulsive threshold associated with decreased concentrations of brain monoamines. LONDON, E. D., S. B. WALLER, F. J. VOCCI and G. G. BUTERBAUGH 441

Specificity of the learned helplessness model of depression. SHERMAN, A. D., J. L. SACQUITNE and F. PETTY 449

Tactile extinction: Distinguishing between sensorimotor and motor asymmetries in rats with unilateral nigrostriatal damage. SCHALLERT, T., M. UPCHURCH, N. LOBAUGH, S. B. FARRAR, W. W. SPIRDUSO, P. GILLIAM, D. VAUGHN and R. E. WILCOX 455

Alleviation of anisomycin-induced amnesia by pre-test treatment with lysine-vasopressin. JUDGE, M. E. and D. QUARTERMAIN 463

Similar development of tolerance to barbital-induced inhibition of avoidance behavior and loss of righting reflex in rats. RICHTER, J. A., P. S. HARRIS and P. V. HANFORD 467

Alcohol and morphine induced hypothermia in mice selected for sensitivity to ethanol. BRICK, J. and G. P. HOROWITZ 473

Pharmacological manipulation of milk-induced behaviors in three-day-old rat pups. CAZA, P. A. and L. P. SPEAR 481

Effects of profadol on operant behavior in the pigeon. LEANDER, J. D. 487

Behavioral pharmacology of local anesthetics: Reinforcing and discriminative stimulus effects. WOOLVERTON, W. L. and R. L. BALSTER 491

Induction of dependence on ethanol by free-choice drinking in alcohol-preferring rats. WALLER, M. B., W. J. McBRIDE, L. LUMENG and T.-K. LI 501

Brain neurotransmitter turnover correlated with morphine-seeking behavior of rats. SMITH, J. E., C. CO, M. E. FREEMAN and J. D. LANE 509

BRIEF COMMUNICATION

Acute venous catheterization for integrated plasma sample collection in monkey. BREE, M. P., N. K. MELLO, K. L. HARVEY and S. A. WEBB 521

ANNOUNCEMENTS 525

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 16 NUMBER 4 APRIL 1982

CONTENTS

Benzodiazepines: Relationship between pharmacological activity in the rat and in vivo receptor binding. MENNINI, T., S. COTECCHIA, S. CACCIA and S. GARATTINI 529

Postnatal development of a cholinergic influence on neuroleptic-induced catalepsy. BURT, D. K., S. M. HUNGERFORD, M. L. CROWNER and L. A. BAEZ 533

Effect of haloperidol and chlorpromazine on reversal learning of normal and striatectomized rats in a Y-maze. ARUSHANIAN, E. B. and V. A. BATURIN 541

Effect of 6-hydroxydopamine-induced lesions of A10 dopaminergic neurons on aggressive behavior in rats. PUCILOWSKI, O., W. KOSTOWSKI, A. BIDZINSKI and M. HAUPTMANN ... 547

Discriminative stimulus properties of DOM and several molecular modifications. GLENNON, R. A., R. YOUNG and J. A. ROSECRANS 553

A comparison of the behavioral effects of DOM homologs. GLENNON, R. A., R. YOUNG and J. A. ROSECRANS 557

Effects of naloxone and naltrexone on locomotor activity in C57BL/6 and DBA/2 mice. CASTELLANO, C. and S. PUGLISI-ALLEGRA 561

Stereotyped behavior elicited by amphetamine in the rat: Influences of the testes. BEATTY, W. W., A. M. DODGE and K. L. TRAYLOR 565

The effects of methadone on the social behavior and activity of the rat. PLONSKY, M. and P. R. FREEMAN 569

Effects of marihuana cannabinoids on seizure activity in cobalt-epileptic rats. COLASANTI, B. K., C. LINDAMOOD, III and C. R. CRAIG 573

The effects of food deprivation and satiation on oral pentobarbital self-administration in rhesus monkeys. KLINER, D. J. and R. A. MEISCH 579

Long-term effects of fetal ethanol exposure on pituitary-adrenal response to stress. TAYLOR, A. N., B. J. BRANCH, S. H. LIU and N. KOKKA 585

Effect of diphenhydramine on stress-induced changes in brain histidine decarboxylase activity, histamine and plasma corticosterone levels. MAZURKIEWICZ-KWILECKI, I. M. and B. BIELKIEWICZ 591

Interaction of acute and chronic stress with respiration: Modification by naloxone. ISOM, G. E. and R. M. ELSHOWIHY 599

Effects of benactyzine on an equilibrium and multiple response task in rhesus monkeys. FARRER, D. N., M. G. YOCHMOWITZ, J. L. MATTSSON, N. E. LOF and C. T. BENNETT 605

Antibodies to GM1 ganglioside inhibit morphine analgesia. KARPIAK, S. E. 611

The ontogeny of spinal cord monoamines and the post-decapitation reflex. PAPPAS, B. A. and R. INGS 615

Antagonism of morphine-induced behavioral suppression by opiate receptor alkylators. MESSING, R. B., P. S. PORTOGHESE, A. E. TAKEMORI and S. B. SPARBER 621

Isoproterenol alters nonshivering thermogenesis in the Zucker obese rat (fafa). MILAM, K. M., J. S. STERN and B. A. HORWITZ 627

Effect of amphetamine and cocaine on seizure in lead treated mice. BURRIGHT, R. G., P. J. DONOVICK, K. MICHELS, R. J. FANELLI and Z. DOLINSKY 631

Psychological stress enhances noradrenaline turnover in specific brain regions in rats. IIMORI, K., M. TANAKA, Y. KOHNO, Y. IDA, R. NAKAGAWA, Y. HOAKI, A. TSUDA and N. NAGASAKI 637

Use of a single compartment LCEC cell in the determinations of biogenic amine content and turnover. CO, C., J. E. SMITH and J. D. LANE 641

Effects of chronic phencyclidine on fixed-ratio responding: Relation to neurotransmitter receptor binding in rat cerebral cortex. SCHWARTZ, R. D., J. M. MOERSCHBAECHER, D. M. THOMPSON and K. J. KELLAR 647

Opiate antagonists stimulate affiliative behaviour in monkeys. FABRE-NYS, C., R. E. MELLER and E. B. KEVERNE 653

Effects of pentobarbital and cocaine in rats expecting pentobarbital. HINSON, R. E., C. X. POULOS and H. CAPPELL 661

BRIEF COMMUNICATION

A comparison of the effects of pimozide and nonreinforcement on discriminated operant responding in rats. BENINGER, R. J. 667

ANNOUNCEMENTS 671

PHARMACOLOGY BOCHEMISTRY & BEHAVIOR

VOLUME 16 NUMBER 5 MAY 1982

CONTENTS

No evidence for cholinergic mechanisms in the control of spontaneous predatory behavior of the ferret. MEIERL, G. and W. J. SCHMIDT 677

Effects of morphine on fixed interval-induced escape from food reinforcement. SLIFER, B. E. .. 683

Convulsant benzodiazepine Ro 5-3663 has anxiolytic properties. FELDON, J. and M. MYSLOBODSKY 689

A new method for the determination of blood ethanol levels in rodents. POHORECKY, L. A. and J. BRICK 693

Influence of repeated deprivation upon starvation-induced hypovolemia and plasma aldosterone concentration in rats. WRIGHT, J. W. and E. M. SCHULZ 697

Dynorphin-(1–13), dopamine and feeding in rats. MORLEY, J. E., A. S. LEVINE, M. GRACE and J. KNEIP 701

Alcohol-morphine interactions: Oral intake in genetically selected Maudsley rats. SATINDER, K. P. 707

Effects of acute and daily cocaine administration on performance under a delayed-matching-to-sample procedure. BRANCH, M. N. and M. E. DEARING 713

Adrenal catecholamines in rats after severe ethanol intoxication and acute withdrawal. ADAMS, M. A., P. L. PURVIS and M. HIRST 719

Continuous infusion in rats as a method of assessing morphine-like physical dependence for opiates. McCARTHY, P. S., G. METCALF and S. J. HOWE 725

Prevention of reserpine rigidity by alpha-2 adrenergic antagonists. WAGNER, B. H. and R. J. ANDERSON 731

Rotation induced by intranigral phenobarbital: Evidence of barbiturate GABAergic activity. McDEVITT, J. T. and L. M. YUNGER 737

β-Adrenoceptor antagonists may attenuate hyponeophagia in the rat through a serotonergic mechanism. SHEPHARD, R. A., D. A. BUXTON and P. L. BROADHURST 741

Effects of caffeine on schedule-controlled responding in the rat. MELISKA, C. J. and R. E. BROWN 745

Opiate modification of amygdaloid-kindled seizures in rats. STONE, W. S., C. E. EGGLETON and R. F. BERMAN 751

Ethanol elimination rates in mice: Effects of gender, nutrition, and chronic ethanol treatment. ALLEN, D. L., R. G. LITTLE II, J. E. THEOTOKATOS and D. R. PETERSEN 757

Altered adult behavior of mice following postnatal treatment with haloperidol. DALLEMAGNE, G. and B. WEISS 761

Mitigation of the septal lesion syndrome by pre-lesion chronic treatment with haloperidol. MAROTTA, R. F., N. LOGAN, S. RIVERSO and E. L. GARDNER 769

Mechanisms of action of p-chlorophenylalanine in stimulating sexual receptivity in the female rat. WILSON, C. A., R. C. BONNEY, D. M. EVERARD, R. F. PARROTT and J. WISE 777

Effects of various catecholamine receptor antagonists, muscle relaxation and physical hindrance on shuttlebox self-stimulation. LIEBMAN, J. M., N. HALL and J. PROWSE 785

Differential effects of *d*-amphetamine, pipradrol and bupropion on shuttlebox self-stimulation. LIEBMAN, J. M., S. GERHARDT and J. PROWSE 791

Anxiolytic drugs selectively increase preferred duration of rewarding brain stimulation in a shuttlebox test. GERHARDT, S., J. PROWSE and J. M. LIEBMAN 795

Lithium toxicology: Effect of isotopic composition on lethality and behavior. ALEXANDER, G. J., K. W. LIEBERMAN, M. OKAMOTO, P. E. STOKES and E. TRIANA 801

Detection of cholinergic mediation of behavior in 7-, 9-, and 12-day old rat pups. SMITH, G. J., L. P. SPEAR and N. E. SPEAR 805

A comparison of the behavioral effects of proteo- and deutero-N,N-dimethyltryptamine. BEATON, J. M., S. A. BARKER and W. F. LIU 811

Duration of response to pentobarbital of female vs male albino and pigmented rats. WESTENBERG, I. S. and J. M. BOLAM 815

Behavioral effects of intracerebroventricularly administered neurohypophyseal hormone analogs in mice. MEISENBERG, G. and W. H. SIMMONS 819

Naloxone alters alcohol drinking induced in the rat by tetrahydropapaveroline (THP) infused ICV. MYERS, R. D. and E. C. CRITCHER 827

BRIEF COMMUNICATIONS

5α-Androstane-3β,17β-diol binds to androgen and estrogen receptors without activating copulatory behavior in female rats. DOERING, C. H. and B. A. GLADUE 837

Isolation rearing decreases opiate receptor binding in rat brain. SCHENK, S., M. D. BRITT, J. ATALAY and S. CHARLESON 841

Acute and chronic effects of phenytoin on fixed-ratio performance of pigeons. KRAFFT, K. and A. POLING 843

Effect of acute and chronic ethanol pre-treatment on the disposition of phencyclidine (PCP) in the rat. VADLAMANI, N. L., R. B. PONTANI and A. L. MISRA 847

Experimental studies of the abuse potential of *d,l*-glaucine·1.5 phosphate in rhesus monkeys. SCHUSTER, C. R., T. AIGNER, C. E. JOHANSON and T. H. GIESKE 851

Effect of cocaine on afterdischarge threshold in previously kindled rats. STRIPLING, J. S. and C. HENDRICKS 855

Rate dependent inhibition of self-stimulation by apomorphine. CAREY, R. J. 859

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 16 NUMBER 6 JUNE 1982

CONTENTS

Selective action of morphine on reflex expression to nociceptive stimulation in the rat: A contribution to the assessment of analgesia. WARREN, P. H. and J. R. ISON 869

Influence of estrogen and progesterone on behavioral effects of apomorphine and amphetamine. MICHANEK, A. and B. J. MEYERSON 875

Forebrain serotonin and avoidance learning: Behavioural and biochemical studies on the acute effect of p-chloroamphetamine on one-way active avoidance learning in the male rat. ÖGREN, S. O. . 881

Peripherally administered somatostatin reduces feeding by a vagal mediated mechanism. LEVINE, A. S. and J. E. MORLEY 897

Does hypothermia play a relevant role in the glycemic alterations induced by ethanol? OLIVEIRA SOUZA, M. L. and J. MASUR 903

The effects of chronic administration of naltrexone on appetite and water exchange in rats. LANG, I. M., J. C. STRAHLENDORF, H. K. STRAHLENDORF, L. O. LUTHERER and C. D. BARNES 909

Lateralization of zinc in rat brain and its relationship to a spatial behavior. VALDES, J. J., S. W. HARTWELL, S. M. SATO and J. M. FRAZIER 915

Scopolamine does not disrupt spatial working memory in rats. GODDING, P. R., J. R. RUSH and W. W. BEATTY 919

Effect of methaqualone on plasma corticosterone in rats: Possible sites of action. BOGGAN, W. O. and J. S. MEYER 925

A study of the shaking and grooming induced by RX 336-M in rats. GMEREK, D. E. and A. COWAN 929

Testosterone affects food intake and body weight by weanling male rats. NUNEZ, A. A. and M. GRUNDMAN 933

Phencyclidine retards autoshaping at a dose which does not suppress the required response. COVENEY, J. R. and S. B. SPARBER 937

Effects of TRH on acquisition and extinction of shuttlebox-avoidance behavior in Fischer$_{344}$ rats. TAMAKI, Y. and Y. KAMEYAMA 943

Increased fat consumption induced by morphine administration in rats. MARKS-KAUFMAN, R. 949

Pharmacologic control of pemoline induced self-injurious behavior in rats. MUELLER, K. and W. L. NYHAN 957

Animal model of depression: Pharmacological sensitivity of a hedonic deficit. KATZ, R. J. 965

A further parametric study of imipramine in an animal model of depression. KATZ, R. J. and G. BALDRIGHI 969

Animal model of depression: Tests of three structurally and pharmacologically novel antidepressant compounds. KATZ, R. J. and M. SIBEL 973

Further analysis of the specificity of a novel animal model of depression—effects of an antihistaminic, antipsychotic, and anxiolytic compound. KATZ, R. J. and M. SIBEL 979

Depression of learned thermoregulatory behavior by central injection of opioids in cats. CLARK, W. G. and G. L. BERNARDINI 983

Extreme hyperthermia induced in cats by the enkephalin analog FK 33-824. CLARK, W. G., G. L. BERNARDINI and S. W. PONDER 989

Alcohol drinking induced in the monkey by tetrahydropapaveroline (THP) infused into the cerebral ventricle. MYERS, R. D., M. L. McCALEB and W. D. RUWE 995

Naloxone suppresses insulin-induced food intake in novel and familiar environments, but does not affect hypoglycemia. ROWLAND, N. and T. J. BARTNESS 1001

Interaction of diazepam with meperidine or normeperidine on analgesia and lethality. LEANDER, J. D. 1005

Phencyclidine raises kindled seizure thresholds. FREEMAN, F. G., M. F. JARVIS and P. DUNCAN 1009

A comparison of the effects of opiate antagonists on operant and ingestive behavior. SANGER, D. J. and P. S. McCARTHY 1013

Effects of MIF-I, sex, and weight on tonic immobility in lizards (*Anolis carolinensis*). CASHNER, F. M., S. W. DELATTE, T. K. VON ALMEN, G. A. OLSON and R. D. OLSON .. 1017

INDEX TO VOLUME 16 1021